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 Abstract	  
Biopharmaceuticals are due to low stability often administered though injections, but for 
several reasons it is desirable to deliver them orally, via the gastrointestinal tract. It is possible 
to shield the biopharmaceuticals from the harsh environment of the gastrointestinal tract by 
utilizing nanoparticles as drug delivery systems (NDDS). The mucus lining the intestines 
creates a significant barrier for the delivery of nanoparticles to the epithelial cells. More 
information and knowledge on how nanoparticles interact with mucus is still needed to create 
NDDS that efficiently transverse this mucus barrier. Caco-2 cells, the common cell line 
utilized in drug absorption studies, are not compatible with native mucus. A biosimilar mucus 
has recently been developed that is compatible with Caco-2 and has potential as an intestinal 
mucous model system in drug absorption studies. 
 
In this master thesis it was attempted to characterize the adhesion and distribution of 
nanoparticles on and in mucus. By running replicate experiments on pig small intestinal 
mucus (PSIM) and biosimilar mucus, the applicability of biosimilar mucus as an intestinal 
mucous model system for drug absorption studies was evaluated. It was attempted to develop 
a new throughput method, the plate method, which would characterize the adhesion of 
nanoparticles on mucus, and also allow for the testing of different variables on the 
mucoadhesion of the particles. The distribution of nanoparticles in and on mucus was 
characterized by confocal microscopy of fluorescent nanoparticles in and on the two mucous 
systems. Furthermore, the rheological profiles of biosimilar mucus and PSIM were 
investigated and compared.  
 
The plate method looked promising up until it was detected that PSIM and biosimilar mucus 
gave a lot of unwanted background fluorescence, possibly due to Raman scattering. The 
further development of the method was terminated. The results of the distribution studies 
suggested that bisoimilar mucus might be an applicable mucous model system in drug 
absorption studies. They showed that nanoparticles distribute in biosimilar mucus and PSIM 
in a comparable manner, and that the biosimilar mucus did not significantly aggregate or alter 
the nanoparticles, which might prevent the intestinal epithelial cells from nanoparticle uptake. 
The nanoparticle distribution showed no specific patterns relating to the size or charge of 
different nanoparticles. Neither the biosimilar mucus or the PSIM were robust enough for the 
experimental conditions of studying nanoparticle distribution and adsorption of nanoparticles 
on top of the mucus, and were also too dense for the laser of the confocal microscope to 
penetrate properly. The rheological profile of biosimilar mucus was broadly comparable to 
the rheological profile of PSIM. 
 
 Sammendrag 
“Biopharmaceuticals” er på grunn av en generell lav stabilitet administrert via injeksjoner, 
men av flere grunner er det ønskelig å levere de oralt, via mage-tarmkanalen. Det er mulig å 
skjerme “biopharmaceuticals” fra det tøffe miljøet i mage-tarm-kanalen ved å anvende 
nanopartikler som medisin-leverings-systemer (NDDS). Slimlaget i tarmen skaper en 
betydelig barriere for levering av nanopartikler til epitelcellene. Det er stadig behov for 
informasjon og kunnskap om hvordan nanopartikler samhandler med slimet for å skape 
NDDS som effektivt trenger gjennom slimbarrieren. Caco-2 celler er den celle-linjen som 
vanligvis benyttes i opptaksstudier av medisiner over tarmbarrieren, men den er ikke 
kompatibel med naturlig slim. Nylig har det blitt utviklet et “biosimilar slim” som er 
kompatibelt med Caco-2, og som har potensiale som et modellsystem for tarmslim i 
opptaksstudier. 
 
I denne masteroppgaven ble adhesjonen og distribusjonen av nanopartikler på og i tarmslim 
forsøkt karakterisert ved å gjennomføre gjentatte forsøk på tynntarmsslim fra gris (PSIM) og 
biosimilar slim. Anvendelsen av biosimilar slim som et modellsystem for opptaksstudier ble 
vurdert. Det ble forsøkt å utvikle en ny metode, platemetoden, som karakteriserer adhesjonen 
av nanopartikler på slim, og som også gir muligheten til å teste hvordan ulike variabler 
påvirker adhesjonen til nanopartiklene. Distribusjonen av nanopartikler i og på slim ble 
karakterisert ved konfokalmikroskopi av fluorescerende partikler i og på de to slimsystemene. 
Videre ble de rheologiske profilene av biosimilar slim og PSIM sammenliknet. 
 
Platemetoden virket lovende før det ble oppdaget at PSIM og biosimilar slim ga mye uønsket 
bakgrunnsfluorescence, som trolig skyldes ”Raman scattering". Videre utvikling av metoden 
ble da terminert. Resultatene fra distribusjonsstudiene antydet av biosimilar slim kan være et 
brukbart slim-modellsystem i opptaksstudier av nanopartikler, da de viste at nanopartikler 
distribuerer seg på tilsvarende måte i biosimilar slim og PSIM. Det ble også vist at det 
biosimilare slimet ikke aggregerer nanopartiklene i noen stor grad, noe som kan føre til 
redusert partikkel-opptak av epitelcellene i tarmen. Nanopartikkel-distribusjonen viste ingen 
spesielle mønstre knyttet til størrelsen eller ladningen av de ulike partiklene. Verken 
biosimilar slim eller PSIM var robust nok for det eksperimentelle oppsettet der distribusjonen 
av nanopartikler ble studert på toppen av slim, og var så tett at laseren på 
konfokalmikroskopet hadde problemer med å trenge igjennom hele slimprøven. Den 
rheologiske profilen til biosimilar slim var stort sett sammenliknbar med den rheologiske 
profilen til PSIM.  
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1.	  Introduction	  
	  
	   	  
1. Introduction 
1.1	  Scientific	  introduction	  
1.1.1	   Biopharmaceuticals	   and	   challenges	   of	   drug	   delivery	   via	   the	  
gastrointestinal	  tract	  	  
 
The pharmaceutical industry is frequently working on developing new, more efficient and 
safe drugs and pharmaceuticals. The last two decades there has been a growth in the interest 
of biopharmaceuticals, which differ from conventional medicines in several ways. 
Biopharmaceuticals originate from living organisms such as cells, animals or plants, and are 
high molecular proteins and/or nucleic acids. The majority of the market is comprised of 
protein products with various substituents (Crommelin et al., 2003) (Guiochon and Beaver, 
2011). Insulin, for treatment of different types of diabetes mellitus, is considered the 
“original” biopharmaceutical (Walsh, 2005). Though still a small part of the pharmaceutical 
industry, biopharmaceuticals constitutes the fastest expanding sector of the market, and is 
likely to comprise half of the new US Food and Drug Administration (FDA) approved drugs 
in the near future (Staub et al., 2011). In 2012, 18 out of 44 new FDA approved drugs were 
biopharmaceuticals (Rader, 2013). 
 
The advantage of biopharmaceuticals over conventional drugs is a highly selective mode of 
action towards the pathological target and increased safety. In general, the body handles its’ 
own molecules better than the foreign molecules of conventional drugs, and induce less 
toxicity and side effects (D’Haens, 2007) (Sekhon, 2010). Even so, biopharmaceuticals 
generally have low solubility and low stability, which complicates the drug delivery (Ensign 
et al., 2012) (Grazú et al., 2012). The most common route of administration of 
biopharmaceuticals is through painful injections (Crommelin et al., 2003). For convenience, 
patient compliance and lower costs, it is desirable to deliver biopharmaceuticals via the 
gastrointestinal (GI) tract (Grazú et al., 2012) (Kwon et al., 2013).  
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There are however several significant hurdles to overcome in deliverance of 
biopharmaceuticals via the GI tract. The main function of the GI tract is digestion of food, 
which is not a good fit with the natural proteins and nucleic acids that biopharmaceuticals are 
made up of. The major challenge is the harsh environment in the stomach and intestines. The 
pH of the stomach is 1-2.5, while the pH in the small intestines is 6.6-7.5 (Galindo-Rodriguez 
et al., 2005). Furthermore, the gastric fluids of the stomach contain hydrochloric acid and 
pepsin, which degrade proteins. The small intestines contain bile salts and pancreatic juices 
that contain an array of enzymes that degrade proteins, fats and carbohydrates (Galindo-
Rodriguez et al., 2005). 
 
In addition, the mucus layer lining the epithelial surfaces of the GI tract creates a considerable 
barrier to the delivery of biopharmaceuticals, conventional drugs and nanoparticle drug 
delivery systems (NDDS) (Ensign et al., 2012)  (Grazú et al., 2012). Mucus has a constant 
turnover rate, which means that pharmaceuticals have to diffuse “upstream” in the mucus 
layer. This contributes to low bioavailability of many drugs (MacAdam, 1993) (Bhat et al., 
1995). Mucus and its’ properties will be discussed next, before returning to the challenge of 
delivering biopharmaceuticals via the GI tract.  
 
1.1.2	  Mucus	  
 
Mucus is a biological secretion consisting of water (~95 %), mucin glycoproteins, other 
proteins, lipids, inorganic salts, carbohydrates, antibodies, bacteria and cellular debris (Smart, 
2005) (Ensign et al., 2012). Mucus covers the epithelium of all the organs and surfaces of the 
body that is exposed to the external environment, and is often the first contact point when 
pharmaceuticals are entering the body (Bansil and Turner, 2006) (Kwon et al., 2013). Mucus 
is synthesized by goblet cells in single layer epithelia, or salivary glands in multi-
layered/stratified epithelia, which secretes mucus onto the epithelial surface (Smart, 2005). 
 
The main function of mucus in the GI tract is to serve as a semipermeable barrier. It protects 
the exposed epithelial surfaces by trapping pathogens, and clears them out through faecal 
elimination (Ensign et al., 2012) (Kwon et al., 2013). At the same time the mucus barrier in 
the intestines allows rapid passage of selected ions, gasses, nutrients and some proteins (Lai et 
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al., 2009b). Furthermore, the mucus layer is an excellent lubricant, as it enables the transit of 
digestive material, protects the epithelia from mechanical stress and keeps it hydrated (Atuma 
et al., 2001) (Bansil and Turner, 2006). 
 
In one day a human being secretes almost 10 litres of mucus into the GI tract, where most of it 
is digested and reused (Cone, 2009) (Kwon et al., 2013). The composition of mucus is 
continuously regulated, which in turn affects physiological and protective properties of the 
mucus (Cone, 2005). The thickness of the mucus in the GI tract varies from 50-300 µm 
(Ensign et al., 2012), where the thickest layer can be found in the stomach and the colon 
(Lichtenberger, 1995). 
 
1.1.2.1	  Mucins	  and	  the	  mucus	  gel	  network	  
 
The main components of mucus are the mucin glycoproteins, which make up about 2-5 % of 
the wet weight of mucus (Bansil and Turner, 2006). So far there has been found at least 20 
different genes coding for different mucin glycoproteins, expressed in different tissues of the 
body. These constitute the MUC gene family (Bansil and Turner, 2006). Normal GI tract 
mucus contains mucins coded by MUC2, MUC5AC, MUC5B, MUC6 and MUC19 (Antoni et 
al., 2013). Different mucins are classified by their protein backbone (Rose and Voynow, 
2006).  
 
Mucin monomers have a long and flexible protein backbone, consisting of tandem repeats of 
proline, threonine and/or serine residues. The backbone is heavily glycosylated through O-
glycosylation of short hydrophilic glycans (Cone, 2009) (Lai et al., 2009a), which contains 
sialic acids and sulphate groups, giving the mucins an overall negative charge (Lichtenberger, 
1995). The regions coated with negatively charged glycans are interspersed by naked 
hydrophobic regions rich in cysteins, which gives the naked regions a globular shape (Cone, 
2005)  (Lai et al., 2009b). The terminal ends of the mucin monomers are also rich in cysteins, 
enabling polymerization of mucin monomers via disulphide bonds (Cone, 2009). The mucin 
polymers range from 10 to 40 MDa in size (Lai et al., 2009a). The structure of mucins is 
illustrated in Figure 1.1. 
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Figure 1.1 The structure of mucin at different magnifications, indicated to the right (Cone, 2009).  
 
In the presence of water mucins starts to overlap, interpenetrate and form a mesh network, 
which leads to gelation (Kočevar-Nared et al., 1997). Although several models have been 
suggested, the exact structure of the gel matrix of mucus is still not clear. Mucins are assumed 
to be the main contributors to the structure of the gel matrix (Sellers et al., 1991) (Taylor et 
al., 2005a), but the non-mucin components of the mucus, like other proteins, lipids and 
nucleic acids are also thought to play a role (Taylor et al., 2003). The mechanism behind this 
is somehow uncertain. An array of various interactions that flicker on and off is assumed to 
contribute to the formation of the mucus gel structure, like hydrophobic bonds, electrostatic 
and ionic interactions, H-bonds and van der Waals interactions. These are assumed to occur 
both between the carbohydrate side chains and the hydrophobic regions of the mucin 
molecules (Kočevar-Nared et al., 1997) (Cone, 2009). Taylor and colleagues (Taylor et al., 
2003) showed that the gel network consists of both transient and non-transient interactions. It 
was also indicated that an equilibrium exists between molecules or parts of molecules 
involved in gelation, and molecules or part of molecules not involved in gelation, leading to 
“dangling chain ends” (Taylor et al., 2003).  
  
The interactions of the mucin polymers and the non-mucin components of the mucus not only 
contribute to the gelling of the mucus, but also contribute to physical properties like 
adhesiveness (mucoadhesion) and viscoelasticity. Adhesiveness makes mucus stick to most 
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surfaces and small particles due to the range of low affinity bonds that flicker on and off 
between the mucin fibres and surface/particle(Cone, 2005) (Bansil and Turner, 2006).  
 
The various interactions in the mucin mesh resists flow, and contributes to giving mucus 
rheological viscoelastic properties (Kočevar-Nared et al., 1997), which means is has both 
viscous and elastic behaviour in response to an applied force (Girod et al., 1992) (Smidsrød 
and Moe, 2008). Appropriate viscoelastic properties are crucial for the functions of GI tract 
mucus. Dominant viscoelastic behaviour maintains the protective barrier the mucus layer 
constitutes, and rheological reversibility makes sure that mucus can be reused. Rheological 
reversibility includes shear thinning, where the rheological properties are dependent on strain 
or shear, and thixotropy, where the rheological properties in addition to being dependent on 
strain or shear, also are dependent on time (Girod et al., 1992) (Barnes, 1997) (Moller et al., 
2006) (Ensign et al., 2012). The viscoelastic properties are regulated primarily by the mucin 
content, but also by the ion, lipid and water content of the mucus (Ensign et al., 2012). 
 
1.1.3	  Nanoparticles	  and	  nanoparticle	  drug	  delivery	  systems	  
 
The mucus lining the GI tract is a complex material, and constitutes a significant hurdle in the 
oral delivery of biopharmaceuticals. One solution that might overcome this hurdle, and at the 
same time deal the challenge of the harsh environment in the GI tract, could be utilization of 
nanoparticles (Ensign et al., 2012). 
 
Nanoparticles are particles in the size range of 10-9-10-7 meters, and they have been 
thoroughly studied as potential drug delivery systems (NDDS) the past few decades (Orive et 
al., 2004). The first nanoparticle drug delivery system was approved on the market in 1995, 
and since then numerous others have been accepted (Grazú et al., 2012). Nanoparticle drug 
delivery systems come in many designs; from organic liposomes, polymer-drug conjugates 
and dendrimers to inorganic nanoparticles such as carbon nanotubes, metals, silica and 
semiconductor quantum dots. Nanoparticles for medical applications are defined as particles 
with a size between 1 and 1000 nm (Grazú et al., 2012).  
 
 6 
	  
1.	  Introduction	  
	  
	   	  
Nanoparticle drug delivery systems have great potential as vectors of biopharmaceuticals 
because of the many advantages they offer. They have better bioavailability than most 
pharmaceuticals because of enhanced water solubility and small size, which enhance 
interactions with cell membranes and proteins in the same size range. Nanoparticles are very 
applicable, and can be engineered with coatings or ligands that e.g. prolong circulation in the 
blood system, target the particle to a specific organ, cell or organelle, or enhance drug release 
control at the target site. As a result of the specific targeting the drug dose can be lowered, 
which reduces side effects and is more cost-efficient (Orive et al., 2004), (Grazú et al., 2012) 
(Laroui et al., 2012).  
 
Regarding the obstacles of biopharmaceutical delivery via the GI tract, polymer and lipid 
nanoparticle carriers could be designed to entrap the biopharmaceutical. Entrapment in a 
suitable nanocarrier would protect the pharmaceutical from the harsh environment and 
degradable enzymes in the GI tract (Wong, 2010) (Ensign et al., 2012). Different coatings 
could also target the nanoparticles to the small intestine (Grazú et al., 2012). 
 
Assuming the nanoparticles are shielded from the harsh environment of the GI tract, there are 
three possible routes they can take (Florence, 1997) (Ponchel and Irache, 1998); (i) Direct 
transit through the system, ending in faecal elimination. (ii) Adherence of particles to the 
mucin molecules (mucoadhesion), followed by mucus clearance and faecal elimination. (iii) 
Transport or diffusion across the mucus barrier (through the mucin matrix) where uptake of 
the particles takes place through the M-cells in the Peyers patches, isolated follicles of the 
gut-associated lymphoid tissue and/or via the normal intestinal enterocytes (Florence, 1997). 
Transport across the mucus layer and particular uptake is affected by factors like particle size, 
ionization/surface charge, hydrophobicity and the presence or absence of surface ligands 
(Florence, 1997) (Norris and Sinko, 1997). The majority of nanoparticles typically undergo 
direct transit through the GI tract (Lai et al., 2009a). 
 
To avoid immediate clearance the nanoparticles has to interact with the mucus surface. This 
increase the residence time at the mucosal surface and increase the NDDS concentration 
gradient over the mucus layer (Ponchel and Irache, 1998) (Lai et al., 2009a). Some of the 
obstacles currently being worked with are designing nanoparticle drug delivery systems that 
can diffuse faster through the mucus mesh, or break the mucus barrier (Ensign et al., 2012).  
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1.1.4	  Absorption	  studies	  and	  mucous	  model	  systems	  
 
The faith of nanoparticles in the intestines is studied in nanoparticle drug delivery studies, or 
more generic; absorption studies. Caco-2 is a cell line that cultured under specific conditions, 
resembles the enterocytes that lines the small intestines, and is the standard cell line utilized in 
absorption studies of drugs over the epithelial surfaces of the intestines (Hidalgo et al., 1989)  
(Boegh et al., 2014). Caco-2 cells do not produce mucus, and has to be supplemented with 
mucus in order to get a representative in vivo small intestine situation (Boegh et al., 2014). 
 
The mucins and mucus of pig stomachs has been widely studied as a mucous model system, 
because of the similarities in anatomy and physiology between pigs and human stomachs. 
Furthermore, there is a similarity in the sequence of the pig gastric mucin and the human 
gastric mucin MUC5AC (Celli et al., 2005). It has also been shown that mucus from the 
stomach and the small intestine has similar viscoelastic behaviour and properties (Sellers et 
al., 1991) (Lai et al., 2009b). Consequently, extracted mucus from the stomachs or intestines 
of pigs could have been a good alternative for utilization together with Caco-2 cells in drug 
absorption studies.  
 
However, pig small intestinal mucus (PSIM) or pig gastric mucus is not suited for utilization 
together with the Caco-2 cells for various reasons. The main reason is poor compatibility 
between the cells and the mucus because the mucus disrupts the monolayer of Caco-2 cells 
(Bøgh et al., 2013)  (Boegh et al., 2014). Also, it is challenging working with native mucus, as 
the samples are inhomogeneous and contains various amounts of contaminants expected to be 
found in the intestines, like undigested food, debris, luminal fluids, degradable enzymes etc. 
(Groo and Lagarce, 2014). Native mucus samples often show a lot of variation both in content 
and properties from different physiological sites, between individuals and between species. 
Furthermore, certain collection methods are known to e.g. stimulate water secretion, altering 
the mucus’ properties (Girod et al., 1992) (Groo and Lagarce, 2014).  
 
Researches at the University of Copenhagen have in connection with the EU-project, 
COMPACT, developed a biosimilar mucus with inspiration from Lahred et al. (Larhed et al., 
1998). The biosimilar mucus was originally developed for cell compatibility with the CaCo-2 
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cells for  “assessment of the effect of mucus on drug adsorption” (Bøgh et al., 2013). The 
viscoelastic properties have also been optimized for a comparable rheological profile with pig 
intestinal mucus (Bøgh et al., 2013) (Boegh et al., 2014). The main components of the 
biosimilar mucus are Sigma pig gastric mucins type II: crude, high molecular weight 
polyacrylic acid (PAA), lipids and bovine serum albumins (BSA) (Bøgh et al., 2013).  
 
Besides the compatibility with Caco-2 cells, the biosimilar mucus has several advantages 
compared to native mucus. The artificial mucus mixture is homogenous and hence presents a 
more stable model system, avoiding the contaminations and variations found in native mucus. 
It is readily made in sufficient amounts in the laboratory; it does not require expensive or 
complicated equipment, and is made from relatively cheap commercially available chemicals.  
 
1.2	  Aim	  of	  the	  thesis	  	  
 
The aim of the thesis is to investigate how nanoparticles interact in and with mucus, by 
characterizing the adhesion and distribution of different sized and charged nanoparticles in 
and on pig small intestinal mucus (PSIM) and biosimilar mucus. The overall goal is to get an 
increased understanding of how nanoparticle drug delivery systems might be utilized in 
delivering biopharmaceuticals via the gastrointestinal tract, and evaluate the applicability of 
biosimilar mucus as a model for small intestinal mucus in nanoparticle drug delivery studies. 
 
The main focus is to develop a new high throughput method of characterizing the adhesion of 
different sized and charged nanoparticles on PSIM and biosimilar mucus, where different 
variables can be incorporated to check how they affect the mucoadhesion of the particles. The 
method is an attempt to mimic the intestinal situation in vivo. The distribution of different 
nanoparticles on and in PSIM and biosimilar mucus will also be investigated for an increased 
understanding of the nanoparticles’ encounter with mucus, and how mucus interacts with the 
nanoparticles as a function of charge and size.  
 
Working with both PSIM and biosimilar mucus will give a better understanding of the 
differences and similarities between the two mucous model systems regarding the adhesion 
and distribution of nanoparticles. In this way the applicability of biosimilar mucus in that 
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particular area of absorption studies can be evaluated. Furthermore, the rheological profile of 
the biosimilar mucus is to be characterized and compared to the rheological profile of the 
PSIM. The biosimilar mucus has been developed to produce a comparable rheological profile 
to PSIM, but it is desirable to further investigate the similarities and differences of the 
rheological profiles of the two mucous systems by looking at other rheological parameters 
than what has previously been described (Bøgh et al., 2013). This will give a better basis for 
evaluation of biosimilar mucus. 
 
The next section gives an introduction to the principles behind the scientific techniques 
utilized for the investigation of distribution and adhesion of nanoparticles on mucus and 
rheological measurements on mucus. 
 
1.3	  Technical	  introduction	  
1.3.1	  Fluorescence	  and	  scientific	  methods	  utilizing	  fluorescence	  
 
The characterizing of how nanoparticles adheres to and distributes on and in mucus requires 
methods to image and detect the nanoparticles. Fluorescent nanoparticles are suitable for this 
task, as fluorescence has high sensitivity toward detection (Lakowicz, 2006), and can be 
utilized both for imaging by confocal microscopy (distribution studies) and fluorescence 
intensity measurements by a plate reader (adhesion studies).  
 
1.3.1.1	  Introduction	  to	  fluorescence	  
 
Luminescence is the phenomena of emission of light from a given material. This happens 
when “disturbing” energy is absorbed and causes the excitation of loosely held electrons. The 
excited electron is in an unstable state, and returns to the more stable ground state by emitting 
a photon, detected as luminescence. Dependent on the lifetime, luminescence is divided into 
two categories; phosphorescence and the more common fluorescence (Lakowicz, 2006) 
(Henderson et al., 2009). The lifetime of luminescence is defined as the average time between 
the excitation of an electron and the return to the ground state. The fluorescence lifetime is 
from 1 to 100 nanoseconds, and the lifetime of phosphorescence is typically from 
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milliseconds to seconds (Lakowicz, 2006) (Henderson et al., 2009). The concept of 
fluorescence is illustrated by a Jakobski energy diagram in Figure 1.2. 
 
 
Figure 1.2 A Jakobski energy diagram, explaining the concept of fluorescence. Excitation light is 
absorbed by an electron, causing it to gain energy and jump to an excited, unstable state. During the 
short excitation period some energy is dissipated by molecular collisions or transferred to a nearby 
molecule.  The remaining energy is emitted as a photon to relax the electron back to the stable ground 
state. Modified from (Snider, 2013).  
 
Fluorescence is normally emitted from aromatic molecules, collectively termed fluorophores. 
The emission wavelengths are characteristic for the specific molecular conformation of each 
fluorophore. Emission data are usually presented by emission spectra where the intensity of 
the fluorescence is plotted against wavelength, so that the emission maxima can be found. 
Generally the same emission spectrum is obtained regardless of the excitation wavelength. 
The energy of the absorption is higher than the energy of the emission (called a Stokes shift), 
and is the reason a substance is excited by high-energy waves/radiation and emits photons of 
lower wavelengths (Lakowicz, 2006).  
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Fluorescence has high sensitivity towards detection, and the utilization of fluorescence 
technology has within the three last decades had a dramatic growth in many scientific 
disciplines. This includes methods and techniques like fluorescence spectroscopy, time-
resolved fluorescence, flow cytometry, fluorescence imaging, genetic analysis, DNA 
sequencing etc. (Lakowicz, 2006).  
 
1.3.1.2	  Laser	  scanning	  fluorescence	  confocal	  microscopy	  
 
Laser scanning fluorescence confocal microscopy, short: confocal microscopy, is an imaging 
technique used to obtain sharp in focus images. Conventional fluorescence microscopes 
continuously illuminate the whole depth of the sample, and detect emitted light from the focal 
plane of interest in addition to all the out-of-focus light. Confocal microscopy differs from 
conventional fluorescence microscopes by its ability to focus all the light in one spot in a 
focal plane of interest, and filter away light that is not in focus using optical pinholes (Földes-
Papp et al., 2003) (Furrer and Gurny, 2010). 
  
During imaging a laser is filtered through a pinhole, and reflected off dichromatic mirrors 
through an objective. The objective focuses the light in a specific point in the plane of interest 
of the fluorescent sample and excites the fluorophores. The fluorescence light is emitted back 
through the lens, and filtered through a pinhole that is located in a conjugate plane right in 
front of a photomultiplier/detector. Only the light reflected from the focal plane is detected 
because the light coming from other planes in the sample cannot pass through the selective 
pinhole. The smaller the pinhole is, the less out-of-focus light reaches the detector. The 
pinhole eliminates out of focus objects or blur that will occur in an image from a conventional 
fluorescence microscope, and makes it possible to obtain sharp images from thicker samples. 
As all the light is focused into one spot, the entire sample has to be scanned in order to obtain 
a complete 2D or 3D image (Földes-Papp et al., 2003) (Furrer and Gurny, 2010). A schematic 
presentation of the principle behind confocal microscopy is presented in Figure 1.3. 
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Figure 1.3 The principle behind a laser scanning fluorescence confocal microscopy. A laser is filtered 
through a pinhole, reflected off dichromatic mirrors (for convenience only one mirror is shown) and 
through an objective. The objective focuses the light in a specific point in the plane of interest of the 
fluorescent sample and excites the fluorophores (left). The emission light is reflected back through the 
lens, and filtered through a pinhole that is located in a conjugate plane right in front of a 
photodetector. This eliminates out of focus light and blur (right). Modified from (BIOimaging, 2008). 
 
1.3.1.3	  Plate	  reader	  
 
A plate reader is an instrument for performing high-throughput screening of multiple samples.   
Samples are distributed in wells of microtitrer plates, which commonly have 6, 24, 96, 348, or 
1536 wells arranged in a rectangular matrix of ratio 2:3. Plate readers most commonly 
perform different kinds of fluorescence measurements, absorbance measurements, and some 
can also handle light scattering (Lakowicz, 2006) (Jameson and Ross, 2010).  
 
During measurement the microtitrer plate with samples are put inside the reader. The light 
source of the emission light is commonly a xenon flash lamp. The light is directed through an 
excitation monochromator, selecting the desired excitation wavelength. One or more 
dichromatic mirrors reflect the excitation light through an objective and into the sample, 
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either from the top of the plate or the bottom of the plate (only for transparent plates). The 
objective adjusts the excitation light to the desired focal point of the sample, finding the 
correct z-position. The emission light from the excited sample is directed trough an emission 
monochromator and into the fluorescence detector system by the same mirror transmitting the 
excitation light. A simplified sketch of the optics of a plate reader is presented in Figure 1.4. 
The microtitrer plate is moved in the correct xy-position for measurement of the individual 
samples in the wells (Lakowicz, 2006) (Jameson and Ross, 2010). 
 
 
 
Figure 1.4 The optics behind a plate reader. A light source emits light going through an excitation 
monochromator, selecting the desired wavelength of the excitation light. The excitation light is 
reflected in dichromatic mirrors, directing the light through an objective adjusting the correct z-
position and into the sample. From the excited sample the emission light is directed through the same 
dichromatic mirror, through and emission monochromator selecting the desired emission wavelengths 
and into the fluorescence detection system. Modified from (Jameson and Ross, 2010)   (Tecan Austria 
GmbH, 2010). 
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1.3.2	  Rheology	  	  
 
Rheology is the science of flow and deformation of materials (Picout and Ross-Murphy, 
2003) (Wagner Jr et al., 2014). Rheological measurements quantify the elastic and viscous 
properties of a material, and thus give information about the materials’ behaviour (Wyss et 
al., 2007). Viscous properties are connected to loss of energy. In response to an applied force 
a viscous material will flow and deform. When the force is removed, the material will keep 
its’ new shape (Smidsrød and Moe, 2008). Elastic properties are linked to the storage of 
energy. In response to an applied force an elastic material will deform, and the energy will be 
stored in the material. When the force is removed the material will regains its’ original shape. 
Viscoelastic materials show a combination of these two behaviours (Smidsrød and Moe, 
2008). 
 
Dependent on the time scale of the rheological experiment, all materials can behave either as 
solids or liquids (Picout and Ross-Murphy, 2003). At very long time scales solid materials, 
e.g. glass, can flow as liquids under a prolonged stress, and at very short time scales (or at 
very high frequencies) fluid materials behave as solids. The quantity of viscous to elastic 
behaviour in a material is thereby determined by the time scale of the experiment (Picout and 
Ross-Murphy, 2003). Viscoelastic properties of a material can be quantified by e.g. 
oscillatory rheological measurements (Wyss et al., 2007).  
 
1.3.2.1	  Oscillatory	  measurements	  and	  rheometer	  set-­‐up	  
 
For biological liquids and gels, the cone and plate rheometer is most commonly used, in 
combination with oscillatory measurements (Lai et al., 2009b). Small deformation oscillatory 
measurements is non-destructive, and provide information about viscosity and elasticity of a 
material without changing the structure made up of non covalent bonds (Kočevar-Nared et al., 
1997). The oscillating cycle corresponds to a sinusoidal curve, where the applied strain is the 
amplitude and the frequency is the wavelength (Zhong and Daubert, 2013). During a 
rheological measurement with cone and plate geometry, a sample is put on top of a plate and a 
shallow inverted cone is lowered on top of the sample (Lai et al., 2009b). The cone oscillates 
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at predetermined rates, and the plate is stationary while measuring the torque (Wagner Jr et 
al., 2014). Figure 1.5 illustrates the plate and cone set-up. 
 
 
 
 
Figure 1.5 The set-up of a rheometer. The material sample is put on the plate and the cone is lowered 
on top of it before the measurements starts. 
 
The strain/amplitude and frequency of the measurement is known, and the rheological 
measurement finds the relationship (phase lag) between stress and strain from the applied 
strain and the measured torque, see Figure 1.6. From this relationship rheological variables 
like phase angle, apparent viscosity, storage and loss moduli describing the viscoelastic 
behaviour of the sample is found (Lai et al., 2009b) (Zhong and Daubert, 2013). 
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Figure 1.6 The phase lag between the stress and strain waves of a perfectly elastic material (left) and a 
perfectly viscous material (right). A perfectly elastic solid will immediately respond to the stress, and 
the phase angle between the two waves is 0 °. A perfectly viscous material will have a strain wave that 
is 90 ° out of phase with the stress wave. A viscoelastic material will behave in between these two 
extremes. Modified from (Society of Plastics Engineers, 2012). 
 
The phase lag between the sinusoidal wave of the applied strain and the resultant stress wave, 
or vice versa, is quantified by the phase angle, δ, which gives the relationship between the 
storage modulus (G’) and the loss modulus (G’’) (Girod et al., 1992). A perfectly elastic 
material respond to the strain immediately, and the stress wave will be exactly in phase with 
the strain wave, giving a phase angle of 0° (Zhong and Daubert, 2013). For a perfectly 
viscous liquid the stress wave would be 90° out-of-phase with the strain wave (Picout and 
Ross-Murphy, 2003). For a viscoelastic material the phase angle will have values between 0° 
and 90°. If 0° < δ < 45° the storage modulus (G’) has greater values than the loss modulus 
(G’’), and the material will show a more solid like, than liquid like, behaviour. If 45° < δ < 
90° the loss modulus (G’’) has greater values than the storage modulus (G’), and the material 
will show a more liquid like behaviour (Smidsrød and Moe, 2008). However, this is 
frequency dependent, and different pre-set frequencies of the measurements may yield 
different behaviour of samples (Lai et al., 2009b). 
 
The relationship between the phase angle (δ), storage modulus (G’), loss modulus (G’’) and 
the complex shear modulus (G*) is explained by equation 1 and equation 2, and illustrated in 
Figure 1.7 (Picout and Ross-Murphy, 2003). The meaning of the different rheological 
parameters is explained in the next section. 
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tan δ = G’’/G’          (1) 
 
G* = (G’2 + G’’2)1/2          (2) 
Figure 1.7. The relationship between the storage modulus (G’), the loss modulus (G’’), the complex 
shear modulus (G*) and the phase angle (δ). Modified from (Chaplin, 2012). 
 
1.3.2.3	  Important	  rheological	  variables	  
 
Rheological measurements yield a lot of data of from various rheological variables. The 
following list explains in more detail the meaning behind the rheological variables considered 
most important for this thesis. 
 
• Stress, τ, is defined as the force acting per area, and has the unit Pascal (Pa). Stress 
produces a deformation or strain (Picout and Ross-Murphy, 2003) (Zhong and 
Daubert, 2013).  
 
• Strain, γ, is defined as the amount of deformation relative to the original dimensions. 
Stain in dimensionless (Picout and Ross-Murphy, 2003) (Zhong and Daubert, 2013).  
 
• The loss modulus or viscous modulus, G’’, is a measure of the viscous component of 
flow. It characterizes the fluid-like contributions to the measured stress response. The 
higher the value of G’’ is, the more liquid-like is the behaviour of the material 
(Smidsrød and Moe, 2008) (Wagner Jr et al., 2014).  
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• The storage modulus or the elastic shear modulus, G’, is a measure of the recoverable 
portion of the elastic deformation. It characterizes the solid-like contributions to the 
measured stress response. A high value of G’ indicates high elastic properties of a 
material (Wyss et al., 2007) (Wagner Jr et al., 2014). 
 
• The phase angle, δ, is a measure of the phase difference between the applied strain 
wave and the resultant stress wave, or vice versa, and gives the relationship between 
the loss modulus (G’’) and the storage modulus (G’) (Picout and Ross-Murphy, 2003).  
 
• The complex shear modulus, G*, is the ratio of the stress amplitude to the imposed 
strain amplitude, or vice versa (Picout and Ross-Murphy, 2003). 
 
1.3.2.3	  Rheological	  measurements	  
1.3.2.3.1	  Strain	  Sweeps	  	  
 
The stability of a material can be determined by running a strain sweep, where oscillating 
strains of increasing/decreasing values are applied to a material at a fixed frequency (Zhong 
and Daubert, 2013). The log-log plot where the rheological variables are plotted against the 
strain can be divided into two regions; (1) the linear viscoelastic region where the strain is not 
affecting the entanglements, interactions and bonds of the material and (2) a region where the 
imposed strains starts to disentangle and break interactions and bonds in the material (Zhong 
and Daubert, 2013). The linear viscoelastic region is recognized by a horizontal, or even 
slightly convex graph of the rheological parameters, and ends when the absolute values of the 
parameters start to decrease (Zhong and Daubert, 2013), see Figure 1.8. The information of 
which strains are within the linear viscoelastic region is utilized in a succeeding frequency 
sweep on the same sample, to ensure that the frequency sweep is run under non-destructive 
conditions.  
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Figure 1.8 An illustration of the appearance of a strain sweep used to determine the linear viscoelastic 
region of a material. In the linear viscoelastic region the rheological variables are independent on the 
applied strain. Modified from (Zhong and Daubert, 2013). 
 
1.3.2.3.2	  Small	  deformation	  frequency	  sweeps	  	  
 
A frequency of an oscillation is the reciprocal of the time it takes for the cone to complete an  
oscillating cycle of the sinusoidal curve (Zhong and Daubert, 2013). Frequency sweeps gives 
information about the mechanical spectra of a material, which is the frequency dependency of 
the materials behaviour. In a frequency sweep the strain or stress is fixed at a value within the 
linear viscoelastic region, and the cone is set to oscillate at increasing frequencies (most 
commonly) (Zhong and Daubert, 2013). A change of frequency from low to high corresponds 
to a change in the wavelength of the sinusoidal curve from long to short. Since the changing 
variable of a frequency sweep is the frequency of the oscillation, the behaviour seen in a 
frequency sweep is due to time dependent effects of different types of entanglements, links 
and interactions in the material. In addition, the relationship between the storage modulus 
(G’) and loss modulus (G’’) can tell if the material should be classified as a gel, concentrated 
solution or diluted solution (Zhong and Daubert, 2013). For gels, like mucus, the absolute 
values of the storage modulus (G’) is greater than the absolute values of the loss modulus 
(G’’) (Zhong and Daubert, 2013).  
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2. Materials & Methods 
2.1	  Materials	  
2.1.1	  Nanoparticles	  (FluoSpheres®)	  
 
Polystyrene based fluorescent nanoparticles (FluoSpheres®) from Invitrogen (Paisley, UK), 
provided in 2 % aqueous solutions, utilized in the distribution experiments are together with 
their properties summarized in Table 2.1 and Table 2.2. The nanoparticles utilized in the 
development of the plate method are together with their properties summarized in Table 2.3. 
 
The PEGylated particles are carboxylate-modified 200 nm yellow-green FluoSpheres® 
coated with polyethylene glycol (PEG) by Morten Johnsen Dille. The particles have a 
calculated zeta-potential of -10.92 mV. 
 
Table 2.1 The nanoparticles mixed into and put on top of PSIM and biosimilar mucus samples during 
the distribution experiments.  
Surface (charge) Size (diameter) Colour Excitation/emission 
maxima (nm) 
Carboxylate-modified (-) 200 nm yellow-green 505/515 
Carboxylate-modified (-) 100 nm yellow-green 505/515 
Carboxylate-modified (-) 1 µm yellow-green 505/515 
Amine-modified (+) 200 nm yellow-green 505/515 
Amine-modified (+) 100 nm yellow-green  505/515 
PEGylated (-) 200 nm yellow-green 505/515 
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Table 2.2 The nanoparticles mixed into Sigma mucin solutions and dissolved pig gastric mucin in the 
distribution experiments.  
 
Table 2.3 The nanoparticles utilized in the development of the plate method. 
 
2.2.2	  FluoroNunc™	  microtitrer	  plates	  
 
The microtitrer plates utilized in the plate method were of the type FluoroNunc™ 96-well 
black plates, coated with MaxiSorp™(Thermo Scientific, VWR International). The plates had 
a recommended working volume of 350 µL.  
 
2.2.3	  Glass	  chambers	  
 
The chambered coverglass utilized in the distribution experiments were of the type Lab-Tek® 
Chambered #1.0 Borosilicate Coverglass System (Thermo Fisher Scientific Inc., New York, 
USA). There were 8 chambers/wells on each slide with an area of 0.8 cm2 and a 
recommended working volume of 0.2-0.4 mL. 
 
Surface (charge) Size (diameter) Colour Excitation/emission 
maxima (nm) 
Carboxylate-modified (-) 200 nm yellow-green 505/515 
Carboxylate-modified (-) 100 nm yellow-green 505/515 
Amine-modified (+) 200 nm yellow-green 505/515 
Surface (charge) Size (diameter) Colour Emission/excitation 
maxima (nm) 
Carboxylate-modified (-) 200 nm yellow-green 505/515 
Carboxylate-modified (-) 200 nm red 580/605 
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2.2.4	  Sample	  preparations	  
2.2.4.1	  Pig	  small	  intestinal	  mucus	  
 
Pig small intestinal mucus (PSIM) was collected from pig intestines, delivered by Gilde 
slaughterhouse in Steinkjer, from newly slaughtered pigs. The intestines were cut open, and 
the mucus carefully scraped off with a spatula. The mucus was divided in aliquots, and stored 
in a -18 °C freezer. The mucus was thawed on the lab bench before utilization. 
 
2.2.4.2	  Biosimilar	  mucus	  
 
Biosimilar mucus was prepared according to a protocol optimized at the University of 
Copenhagen (Boegh et al 2013). A lipid mix were made by mixing linoleic acid (0.11 % 
(w/v)) (Sigma Aldrich co., St.Louis, USA), cholesterol (0.36 % (w/v) (Sigma Aldrich co., 
St.Louis, USA) and phosphatidylcholine (0.18 % (w/v)) (Sigma Aldrich co., St.Louis, USA) 
in an eppendorf tube and then adding polysorbate 80 (0.163 % (w/v) (Sigma Aldrich co., 
St.Louis, USA). An isotonic 10 mM HEPES buffer (Sigma Aldrich co., St.Louis, USA) 
containing 1.3 mM CaCl2 (Merck KGaA, Darmstadt, Germany), 1.0 mM MgSO4 (Merck, 
Darmstadt, Germany) and 137 mM NaCl (Merck KGaA, Darmstadt, Germany) were added 
and the mixture stirred with a magnetic mixer until homogeneity occurred. In another 
container high molecular polyascorbic acid (PAA) (0.9 % (w/v))  (Reckitt & Coleman 
Products, Kingston Upon Hull, UK) was dissolved in portions in 10 mM HEPES buffer 
containing 1.3 mM CaCl2 and 1 mM MgSO4 under magnetic stirring. Sigma porcine gastric 
mucin type II: crude (5 % (w/v)) (Sigma Chemical co., St.Louis, USA) were stirred into the 
polymer mixture in portions, and 15 µL of 5 mM NaOH were added for each mL mucus made 
to increase the pH. Under magnetic stirring, bovine albumin serum (3.1 % (w/v)) (Sigma 
Chemical co., St.Lous, USA) was added followed by the addition of the lipid mixture. The 
amount of lipid mixture to polymer solution was 1:9. The pH was adjusted to 7.4 using 
NaOH. Before utilization the biosimilar mucus were stored at 4 °C over night. 
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2.2.4.3	  Pig	  gastric	  mucin	  	  
Purified pig gastric mucins were obtained from Professor J.P. Pearson at Institute for Cell and 
Molecular Biosciences, University of Newcastle upon Tyne. The purification protocol is 
listed in Appendix A.1.  
Purified pig gastric mucins were dissolved in physiological NaCl water to a total 
concentration of 5 %. The mucins were mixed in by careful magnetic stirring at 4°C over 
night 
 
2.2.4.4.	  Sigma	  mucin	  solutions	  
 
Two different Sigma mucin solutions were made. The first were prepared by adding Sigma 
mucin type II in portions to physiologic NaCl water under magnetic stirring, to a total 
concentration of 5 %. This solution was utilized in the distribution experiments.  
 
The Sigma mucin solutions utilized in the rheological measurements were prepared by adding 
Sigma mucin type II in portions to 10 mM HEPES buffer containing 1.3 mM CaCl2 and 1 
mM MgSO4 under magnetic stirring. Three solutions of different concentration were 
prepared, 5 % (w/v), 8 % (w/v) and 10 % (w/v). The solutions were stored at 4 °C over night, 
and stirred with a magnetic stirrer prior to measurements. 
 
2.2.4.5.	  Agar	  gel	  
  
Dried agar (Becton Dickinson Company Sparks, USA) was dissolved in MQ water at 80 °C to 
a total concentration of 5 % (w/v). At 50 °C 0.10 g of the liquid agar were pipetted in a glass 
chamber with a cut of pipette tip, and was allowed to gel in the glass chamber. 
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2.2.4.6	  Nanoparticle	  solutions	  
 
All the nanoparticle solutions utilized were made by diluting the 2 % (w/v) nanoparticle 
solutions in MQ-water. For each dilution step the solutions were thoroughly mixed by 
vortexing. 
 
A complete list of all the chemicals utilized in the master thesis is enclosed in Appendix A.2. 
 
2.2	  Methods	  
2.2.1	  Distribution	  of	  nanoparticles	  	  
2.2.1.1	  Distribution	  of	  nanoparticles	  in	  mucus	  	  
2.2.1.1.1	  Biosimilar	  mucus	  and	  PSIM	  	  
 
Mucus samples of 0.20 g were weighed up and put in an eppendorf tube by pipetting with a 
cut off pipette tip. Six different nanoparticle solutions were added (see Table 2.1), one in each 
tube, to an end concentration of 0.08 % (w/v). The nanoparticles were thoroughly mixed into 
the mucus with the aid of a spatula and vortexed, before the samples were distributed in 
different chambers of a glass slide with spatulas. The samples were allowed to settle 
overnight at 4 °C before the nanoparticles were images by laser scanning fluorescence 
confocal microscopy. This was performed with PSIM samples and biosimilar mucus samples.  
 
2.2.1.1.2	  Sigma	  mucin	  solutions	  
 
Three replicates of 200 µL Sigma mucin solutions were added in eppendorf tubes by 
pipetting, and three types of nanoparticle solutions (see Table 2.2) were added to an end 
concentration of 0.08 % (w/v), one solution in each of the tubes.  The solutions were added in 
glass chambers and the nanoparticles imaged by laser scanning fluorescence confocal 
microscopy. 
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2.2.1.1.3	  Pig	  gastric	  mucins	  
200 µL dissolved pig gastric mucins were added in eppendorf tubes, and three different types 
of nanoparticle solutions (see Table 2.2), were added to an end concentration of 0.08 % (w/v), 
one in each tube. Each mixture were added in glass chambers, and the samples were imaged 
by laser scanning fluorescence confocal microscopy. 
 
2.2.1.2	  Distribution	  of	  nanoparticles	  on	  top	  of	  mucus 
2.2.1.2.1	  Biosimilar	  mucus	  and	  PSIM	  
 
100 µL mucus were added in glass chamber wells by pipetting with a pipette with a cut off 
pipette tip. The glass slide was put on a weight prior to mucus addition to ensure the right 
amount was added in each well. Six different nanoparticle solutions (see Table 2.1) with a 
concentration of 0.1 % (w/v) were made. 100 µL of each nanoparticle solution were carefully 
pipetted on the top of the mucus samples, one nanoparticle solution in each chamber. The 
nanoparticles were imaged by laser scanning fluorescence confocal microscopy. This was 
performed with both PSIM and biosimilar mucus samples. 
 
2.2.1.2.2	  Pig	  gastric	  mucins	  
 
100 µL of dissolved pig gastric mucins were pipetted into a glass chamber. 0.1 % (w/v) 1 µm 
sized carboxylate-modified nanoparticles were carefully pipetted on top of the pig gastric 
mucin layer, and the nanoparticles were imaged by laser scanning fluorescence confocal 
microscopy. 
 
2.2.1.2.3	  Agar	  gel	  
 
A 5 % (w/v) agar gel was prepared, where 0.10 g was allowed to gel in a glass chamber. After 
gelation 0.1 % (w/v) 1 µm sized carboxylate-modified nanoparticles were put on top of the 
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agar layer, and the nanoparticles were imaged by laser scanning fluorescence confocal 
microscopy. 
 
2.2.1.3	  Imaging	  with	  laser	  scanning	  confocal	  microscopy	  
 
All samples were visualized and imaged in a laser scanning fluorescence confocal microscopy 
of the type Zeiss LSM 510 Meta (Carl Zeiss Microscopy, Jena, Germany) with serial number 
2110000865.  
 
The argon laser (488 nm) was utilized together with a water objective with 40 x 
magnification, a numeric aperture of 0.8 and a working distance of 1.7 mm. For all 
measurements the strength of the laser were set to 10.1 %, and the detector gain and amplifier 
offset were adjusted so that approximately the same fluorescence intensity would be detected 
in each of the samples. The images were analysed/investigated in LSM Image Browser.  
 
2.2.2	  The	  plate	  method	  
 
The development of the plate method is described in detail in section 3.2. 
 
2.2.2.1	  Fluorescence	  intensity	  measurements	  
 
All the fluorescence intensity measurements were carried out by a Tecan Infinite 200 PRO 
(Tecan Austria GmbH, Salzburg, Austria) plate reader with serial number 1111001422, in 
combination with the software Tecan iControll. Before each measurement the excitation 
maxima, emission maxima and z-position were set. The yellow-green and red nanoparticles 
had ex./em. maxima of 505/515 nm and 580/615 nm respectively. The excitation and 
emission maxima used as “standard” ex./em. wave-lengths were 495/353 nm for the yellow-
green particles, and 580/615 nm for the red nanoparticles. This was due to a requirement of at 
least 35 nm between the set excitation maxima and the emission maxima to prevent the 
xenon-lamp from transmitting light directly into the fluorescence detector, which would yield 
false results. In all measurements at least one blank sample of MQ-water were included. 
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2.2.3	  Rheological	  measurements	  
 
All rheological measurements were run on a Rheologica StressTech (Rheologica, Lund, 
Sweden) instrument with serial number 903-31111, with cone and plate geometry. The cone 
used in the measurements of the biosimilar mucus and PSIM had a diameter of 40 mm and an 
angle of 4 degrees. The cone used in the measurements of the Sigma mucin solutions had a 
diameter of 40 mm and an angle of 1 degree. Unless otherwise mentioned all measurements 
were run on 25 °C. Before measurements the cone was lowered to “zero gap”, and an 
appropriate amount of sample was added to the plate. After lowering of the cone the samples 
of PSIM and biosimilar mucus were covered in silicone oil (Dow Corning ® 200/100S fluid 
(VNR International LTD, Butterworth, UK) to avoid evaporation of water from the samples 
during measurement. The software to register the measurements was Rheoexplorer. Microsoft 
Excel and SigmaPlot were utilized for further data analysis.   
 
2.2.3.1	  Rheological	  measurements	  of	  PSIM	  
 
Frequency sweeps kept within the linear viscoelastic region were run on different PSIM 
samples in the interval 0.001-10 Hertz. Ten minutes prior to each of the frequency sweeps, 
strain sweeps were run in the strain region 1*10-5-10 for determination of the linear 
viscoelastic region. Furthermore, up-down strain sweeps in the strain region 1*10-5-10 were 
run. All the strain sweeps were run with a fixed frequency of 1 Hertz, and on different 
samples. 
 
2.2.3.2	  Rheological	  measurements	  of	  biosimilar	  mucus	  
 
Frequency sweeps kept within the linear viscoelastic region were run on individual biosimilar 
mucus samples from two different batches in the region 0.001-10 Hertz. Prior to the 
frequency sweeps, strain sweeps on other samples in the strain range 1*10-5-10 were run for 
determination of the linear viscoelastic region. Up-down strain sweeps in the same strain 
region were also run. All the strain sweep measurements had a fixed frequency of 1 Hertz.  
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2.2.3.3	  Rheological	  measurements	  of	  Sigma	  mucin	  solutions	  
 
For each of the Sigma mucin solutions of 5 % (w/v), 8 % (w/v) and 10 % (w/v) the following 
procedure were conducted;  
 
Strain sweeps in the strain region 1*10-5-100 were conducted with a fixed frequency of 1 
Hertz, instantly followed by a frequency sweep with a fixed strain of 0.05 in the frequency 
region 0.001 – 10 Hertz. This was repeated three times on the same sample, at 15 °C, 25 °C 
and 37 °C.   
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3. Results & Discussion 
3.1	  Distribution	  studies	  of	  nanoparticles	  in	  and	  on	  mucus	  
 
Absorption studies of nanoparticles is an important part of breaking the code to how 
nanoparticle drug delivery systems can be utilized in oral delivery of pharmaceuticals. For a 
successful delivery of the drug load at the target cell/tissue/organ, the nanoparticle drug 
delivery system has to be transported or diffuse through the mucus matrix, and be absorbed by 
the epithelial cells of the intestines (Ensign et al., 2012). This can be studied by Caco-2 cells 
in combination with biosimilar mucus. The biosimilar mucus was originally developed for 
compatibility with the Caco-2 cells. However, compatibility with the cells does not mean that 
biosimialr mucus is an applicable mucus model system in nanoparticle drug delivery studies if 
the mucus affects the nanoparticles in different ways than what native mucus might do.  
 
By studying the distribution of nanoparticles mixed into biosimilar mucus and PSIM, the 
cells’ ability to internalize the given particles after it has diffused through the mucous systems 
is investigated. Nanoparticles of different size and charge will most likely have different 
distribution patterns when mixed into mucus, and the pattern might not be similar when the 
same particle is mixed into different mucous systems. The nanoparticles can distribute in a 
uniform manner or form aggregates. Aggregate formation might prevent or complicate the 
absorption of nanoparticles by the epithelial cells, if the aggregates become too large.  
 
Investigation of how different nanoparticles distributes on top of mucus gives cues to how the 
first encounter of the particles in the intestines might be affected by the particles’ charge 
and/or size. These variables might influence if the ability of the nanoparticles to penetrate the 
mucus mesh, and if the nanoparticles are able to diffuse through the mucus layer at all and 
reach the epithelial cell for internalization. By investigating this in both PSIM and biosimilar 
mucus, a comparison can be made and the applicability of biosimilar mucus in drug 
absorption studies evaluated. 
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3.1.1	  Distribution	  of	  nanoparticles	  mixed	  into	  mucus	  
 
When looking at the distribution of nanoparticles in a confocal microscopy the fluorescent 
nanoparticles are the only thing that will be detected and visualized. This can thus reveal how 
the nanoparticles distribute in mucus; from a complete uniform distribution in the entire 
sample to formation of large aggregates.  
 
An aggregate is a general structure formed by the cohesion between two or more particles 
(Mørk, 1999). The charged nanoparticles will not form aggregates by themselves as they 
repulse each other; hence there must be interactions with components of the mucus matrix 
that induces aggregation formation. It is not straightforward to stipulate the mechanism 
behind the aggregation of nanoparticles in the mucous systems, but it might be due to 
bridging flocculation, in which the components of the mucus acts as polymer flocculants. The 
nanoparticles might interact with different components of the mucus matrix, creating a layer 
of molecules on the nanoparticle surface called the corona. The corona layer might shield the 
repulsive forces of the nanoparticles, and introduce electrostatic interactions, van der Waals 
forces, ionic interactions and/or hydrogen bonds, which enable the particles to aggregate 
(Mørk, 1999). 
 
3.1.1.1	   XY	   images	   of	   the	   distribution	   of	   nanoparticles	   in	   PSIM	   and	   biosimilar	  
mucus	  	  
 
Six types of fluorescent nanoparticles of different size and surface charge were mixed into 
PSIM and biosimilar mucus with an end concentration of 0.08 % (w/v). Furthermore, the 
distribution of three of the nanoparticle types was investigated in two supplement model 
mucous systems; pig gastric mucins (5 % (w/v)) and Sigma mucin type II solution (5 % 
(w/v)). The confocal images of the distribution of nanoparticles captured in the XY direction 
are collected in Figure 3.1. 
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Figure 3.1 XY confocal images captured of various types of fluorescent nanoparticles mixed into 
different mucous systems. The size and charge of the nanoparticles are indicated in the column to the 
left, were A = amine modified (+), C = carboxylate modified (-) and P = PEGylated (-).  
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The images in Figure 3.1 present the distribution of the different nanoparticles in the XY- 
direction in the four mucous systems, and reveals that the different nanoparticles distribute in 
different manners in the four systems. This implies that the distribution of nanoparticles in the 
four mucous systems tested is dependent on the size and surface charge of the particles, and 
the matrix of the mucous system. 
 
Some special considerations regarding the PSIM matrix have to be taken into account when 
studying the nanoparticle distribution resented in Figure 3.1. Black fields are visible in the 
images of the PSIM. This is an artefact observed due to inhomogeneities like debris from the 
intestines, pockets of air etc., which prevents the nanoparticles from distributing in these areas 
of the mucus. This artefact is an expected observation, as the PSIM was extracted from the 
intestines and is a naturally inhomogeneous material (Groo and Lagarce, 2014). Figure 3.2 
presents the distribution of the 200 nm PEGylated particles in the PSIM, which emphasises 
this artefact. Some small black areas can also be seen in some of images of the biosimilar 
mucus (200 nm carboxylate-modified and 200 nm PEGylated nanoparticles), which is likely 
due to air bubbles. No inhomogeneities are expected in this matrix, as it is produced in the 
laboratory by homogenously mixing the ingredients together. 
 
 
Figure 3.2 The distribution of 200 nm PEGylated nanoparticles in PSIM. The arrow points to debris 
in the PSIM matrix. 
 
Upon comparison of the images of the PSIM and biosimilar mucus, the 200 nm PEGylated 
nanoparticles has the most even distribution in both the mucous systems. PEGylation of 
particles are known to modify the biodistribution of particles and enhance their solubility 
 33 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
(Veronese, 2001). Also, PEGylation of particles has been used to improve mobility of the 
particles in mucus and reduce the mucoadhesion of the particles (Lai et al., 2009a). This is 
expected to lead to a more even distribution of the particles, therefore was not a surprising  to 
see that the PEGylated particles had the most uniform distribution. The most uneven 
distribution is of the 100 nm amine-modified and 1 µm carboxylate-modified particles. The 
uneven distribution of the 1 µm sized particles might be due to the large size, which could 
restrict the particles to distribute in “pockets” of the gel matrix where they can fit. Small 
aggregates of nanoparticles are observed in both the PSIM and biosimilar mucus, but are 
somewhat more prominent in the biosimilar mucus. This means that some of the components 
of the biosimilar mucus interact with the nanoparticles and induce larger aggregates than 
when the same nanoparticles interact with components of the PSIM. The largest aggregates 
are in general found in the mucus samples containing negatively charged particles, but 
aggregate formation is also seen in the samples were positively charged particles are mixed 
in. A trend toward larger aggregates of negatively charged nanoparticles might indicate that 
(i) components of the mucous systems are better at shielding the repulsive forces between the 
negatively charged nanoparticles than between the positively charged nanoparticles, and/or 
(ii) that when components interact with the negatively charged particles more aggregation 
forming interactions are introduced than when components of the mucus interact with 
positively charged particles (Mørk, 1999). 
 
The pig gastric mucins (PGM) and Sigma pig gastric mucins are as their names implies, both 
extracted from pig stomachs, and thus of the same origin.  One might expect the nanoparticles 
to distribute in the same manner in these mucin systems, but this is not the case, as seen in 
Figure 3.1. The nanoparticles have a diametrically opposite distribution in the PGM and 
Sigma mucin solutions. The reason for the differences in nanoparticle distribution observed 
between PGM and Sigma mucin is most likely that they have been exposed to different 
purification processes. During a purification process the non-mucin components of the mucus 
are removed, which might free binding sites in the mucin molecules. The Sigma mucins are 
not purified to the same level as PGM, and contains non-mucin proteins and lipids. The 
difference in the accessibility of binding sites on the mucin molecules of Sigma mucin and 
PGM, means they have different interaction potentials, leading to dissimilar aggregation of 
nanoparticles (Mørk, 1999). This is evident when comparing the Sigma solution and PGM 
where the 100 nm carboxylate-modified nanoparticles are mixed in. In PGM the nanoparticles 
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form very large aggregates, which are not observed in the Sigma mucin solution. The intense 
aggregation of the 100 nm carboxylate-modified particles in the PGM is hence an artefact of 
the purification process, which might have given access to new binding sites where the 
nanoparticles of 100 nm size and negative charge can interact. The reason this artefact is not 
observed for any of the 200 nm sized nanoparticles might be that they do not have access to 
the revealed binding sites due the larger size. The observed aggregation of nanoparticles is 
hence dependent on the purification process of the mucins.  
 
Despite the sol-like consistency of the Sigma mucin solutions, all the particles aggregate to 
some degree in the solutions. This indicates that it is not a gel network in itself that prevents 
nanoparticles from distributing in a uniform manner in mucus, but that the Sigma mucins 
interact with the nanoparticles and induce aggregation. Most likely are the mucins partially 
shielding the repulsive forces between the nanoparticles, and introducing electrostatic, ionic 
and or H-bonding interactions that makes the nanoparticles aggregate (Mørk, 1999). 
 
In contrast to the Sigma mucin solutions, the biosimilar mucus does not induce the same 
degree of aggregation, despite also containing Sigma mucins at the same concentration. This 
means that there likely are non-mucin components of the biosimilar mucus that prevents 
formation of larger aggregates by interacting with the nanoparticles, changing their coronas, 
which do not induce the same degree of aggregation. The Sigma mucin solutions cannot be 
directly compared to the PSIM in the same manner as there is no Sigma mucins in the PSIM, 
but the small aggregates observed in the PSIM confirms that native components of the PSIM 
creates structures which do not induce aggregation formation in the same manner as observed 
in the biosimilar mucus.    
 
The differences observed in the distribution of nanoparticles in PSIM, biosimilar mucus, 
Sigma mucin solutions and dissolved PGM highlights the intricacy of working with complex 
molecules like mucins and mucous systems, which is not always straightforward. 
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3.1.1.2	   XZ	   images	   of	   the	   distribution	   of	   nanoparticles	   in	   PSIM	   and	   biosimilar	  
mucus	  
 
The six types of nanoparticles (0.08 % (w/v)) mixed into the PSIM and biosimilar mucus 
were also imaged in the XZ-direction. What is important to keep in mind when investigating 
the confocal images of the XZ-direction, is the lower resolution of these images compared to 
the XY-images, which will not reproduce the same details and accuracy of the XY-images. 
The confocal images captured in the XZ-plane are presented in Figure 3.3. 
 
 
 36 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
 
Figure 3.3 The confocal images captured in the XZ direction of different nanoparticles mixed into 
PSIM and biosimilar mucus. The charge and size of the nanoparticles are indicated in the column to 
the left, were C = carboxylate-modified (-), A = amine-modified (+) and P = PEGylated (-). The 
horizontal plane is the X-plane, and the vertical plane is the Z-plane. 
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From the images in Figure 3.3 it is evident that the laser beam of the confocal microscope has 
problems penetrating the entire height of the mucus and nanoparticle mixtures in the glass 
chambers. This is in particular prominent in the images of the PSIM, where the image 
program automatically inserts black fields in the top and bottom of the image if the width of 
the image (x) is not matched by the height (z) and does not produce a quadratic image. 
 
The reason the confocal laser beam is unable to penetrate the PSIM in particular might be a 
combination of several things. First of all the PSIM has a darker colour and is denser than the 
biosimilar mucus. Second of all, the nanoparticles generally distributes in the PSIM in a more 
uniform manner than in the biosimilar mucus, which will further inhibit the penetration of the 
laser beam. Less of the excitation light is penetrated through the dense PSIM with an even 
distribution of nanoparticles; hence fewer signals will be detected in the mucus layers further 
from the laser.  
 
The image program did not allow for scale bars to be put in the XZ images. However they are 
shown at the same scale and the absolute height in the z-direction of the images is 
summarized in Table 3.1. 
 
Table 3.1 A table with the distance in the z-direction of the XZ confocal images in Figure 3.3.  The 
charge and size of the nanoparticles are indicated in the column to the left, were C = carboxylate-
modified (-), A = amine-modified (+) and P = PEGylated (-). 
 PSIM Biosimilar mucus 
100 nm A 180 µm 290 µm 
100 nm C 83 µm 243 µm 
200 nm A 102 µm 282 µm 
200 nm C 111 µm 250 µm 
200 nm P 143 µm 249 µm 
1 µm C 152 µm 289 µm 
 
 
The 200 nm PEGylated particles distribute in the most uniform manner, both in the PSIM 
matrix and the biosimilar mucus matrix, which was also seen in the XY images. Overall there 
 38 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
is no characteristic trends observed in the distribution of the positively charge particles versus 
the negatively charged particles, despite the overall negative charge of the mucins. This 
means that the mucins and the other components in the mucus must hold an array of different 
types of interactions of attractive and repulsive nature, enabling the interaction of both 
positively and negatively charged particles. This is supported by the knowledge that in a 
mucin gel network several types of interactions contribute to keeping the network together, 
like transient “flickering” bonds such as hydrophobic bonds, electrostatic and ionic 
interactions, H-bonds and van der Waals interactions (Kočevar-Nared et al., 1997) (Taylor et 
al., 2003). With the exception of the somewhat uneven distribution of the 1 µm sized 
carboxylate-modified particles, the size of the nanoparticles seemingly does not affect the 
distribution pattern of the nanoparticles. This implies that the mesh spacing of the gel network 
of the two mucous systems might be large enough to allow for a similar distribution of both 
the 100 nm sized and 200 nm sized nanoparticles. Differences in the mesh spacing of the 
biosimilar mucus and the PSIM might be a contributing factor for the differences seen in 
nanoparticle distribution between the two systems. The more even distribution of 
nanoparticles in the PSIM might indicate that the gel structure of the PSIM is more ordered, 
compared to a less ordered structure in the biosimilar mucus. This might lead to more evenly 
distributed nanoparticles in the PSIM, and less even distributed particles in the biosimilar 
mucu. Considering that the PSIM is of native origin and the biosimilar mucus is an artificial 
mucous system created in the laboratory, this is not unlikely. There is no clear correlation 
between the size of the aggregates in the two mucous systems and the surface charge and/or 
size of the nanoparticles.  
 
As there are no overall trends in the distribution of nanoparticles relating to size or charge, it 
will not be possible to predict the distribution pattern of other nanoparticles based on these 
data.  
3.1.1.3	  Control	  measurements	  
3.1.1.3.1	  Correcting	  for	  dissimilar	  amounts	  of	  nanoparticles	  
 
In the distribution experiments were nanoparticles were mixed into mucus and visualized by 
confocal microscopy, the end concentration of all the different nanoparticles were set to be 
0.08 % (w/v). When different sized nanoparticles have the same concentration, the amount of 
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nanoparticles will differ between the nanoparticle solutions of different sized particles. In 
order to make sure that the differences seen in the distribution patterns of nanoparticles are 
not to some degree affected by differences in amounts of nanoparticles in the mucous 
systems, a control experiment were conducted.  
 
Two nanoparticle solutions of the 100 nm carboxylate-modified nanoparticles were prepared 
and mixed into PSIM. The first solution had a concentration of 0.08 % (w/v) and the total 
amount of particles was calculated to be 2.91*1011 particles. The amount of particles of a 0.08 
% (w/v) 200 nm nanoparticle solution was calculated to be 3.62*1010. Hence, the second 100 
nm solution was made with 3.62*1010 nanoparticles, to a total concentration of 0.01 % (w/v). 
Calculations are found in Appendix B.1. The results after visualizing the nanoparticles by 
confocal microscopy are presented in Figure 3.4. 
 
 
Figure 3.4 The confocal images of 100 nm sized carboxylate-modified fluorescent nanoparticles 
mixed into PSIM. The images of column A represent the sample were the concentration of 
nanoparticles in the mucus is 0.08 % (w/v), and the amount of particles is calculated to be 2.91*1011. 
The images of column B represents the sample were the concentration of nanoparticles in the mucus is 
0.01 % (w/v), and the amount of particles is calculated to be 3.62*1010.  Letters next to the samples of 
column A indicates the XYZ-planes of the images in the corresponding rows. 
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The images in Figure 3.4 reveal no substantial qualitative differences between the two 
samples of PSIM containing nanoparticles of different amounts. This lead to the conclusion 
that the differing amounts of nanoparticles in the mucous systems have not influenced the 
distribution patterns within the nanoparticle concentration regime utilized.  
 
3.1.1.3.2	  Different	  mixing	  procedures	  
 
The mixing procedure of the nanoparticles and mucus of the distribution experiments 
consisted of adding nanoparticles to the mucus sample, mixing with a small spatula and 
vortexing until a homogenous mixture was obtained. To find out if the mixing procedure 
might have had some impact on the distribution patterns of nanoparticles observed, 200 nm 
carboxylate-modified and 200 nm PEGylated nanoparticles were mixed into an aliquot each 
of biosimilar mucus in the making, to an end concentration of 0.08 % (w/v). The 
nanoparticles were mixed into the mucus previous to the step of adjusting the pH to 7.4, 
which thickens the biosimilar mucus mixture to gel consistency. The nanoparticles of the two 
samples were visualized by confocal microscopy, and the results presented together with 
images of the same nanoparticles mixed into biosimilar mucus after it was made, in Figure 
3.5. 
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Figure 3.5 Confocal images in the XY direction of 200 nm sized carboxylate-modified (C) and 
PEGylated (P) nanoparticles mixed in biosimilar mucus. In the images of the first column, the 
nanoparticles are added in biosimilar mucus in the making, and in the images of the second column 
the nanoparticles are added to biosimilar mucus already made. 
The confocal images of Figure 3.5 reveal a quite similar distribution pattern of the 
nanoparticles, independent of how they are mixed into the biosimilar mucus. The 200 nm 
carboxylate-modified particles forms small aggregates in both samples, although some larger 
aggregates are seen in the samples were the particles are added after the biosimilar mucus 
were made. This might be explained by two theories.  
 
First of all the difference might be explained by the difference in pH between the two mucus 
samples when the nanoparticles were mixed in. When the nanoparticles were mixed into the 
biosimilar mucus mixture prior to pH adjustment to 7.4, the PAA of the mixture had not yet 
dissolved and had an overall neutral charge. When the nanoparticles were mixed into the 
biosimilar mucus after completion of the mucus the PAA was dissolved, and hence introduced 
more negative charges to the mixture. These two different conditions might have affected the 
corona layer of the 200 nm carboxylate-modified nanoparticles. Both the nanoparticles and 
the PAA have an overall negative charge, and the nanoparticles and dissolved PAA have to 
compete for the same things like lipids and bovine serum albumin to interact with. Different 
corona layers of the nanoparticles before and after pH adjustment might affect the interactions 
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inducing aggregation. This might be the reason for the bigger aggregates seen in the sample 
where the 200 nm carboxylate-modified nanoparticles are mixed into the mucus after the 
biosimilar mucus were completed.  
 
The second theory that might explain the difference in aggregate size seen between the two 
samples of 200 nm carboxylate-modified nanoparticles, might be the introduction of a gel 
structure in the completed biosimilar mucus. When mixing the nanoparticles into the 
biosimilar mucus gel, particles might accumulate in pockets in the gel structure, which gives 
the impression of aggregate formation when imaged by confocal microscopy.  
 
The nanoparticle distribution of the 200 nm PEGylated nanoparticles have a much more 
similar pattern, where small aggregates can be seen in both of the samples, and are only 
slightly more prominent in the sample were the particles are mixed into the biosimilar mucus 
after the completion of the mucus. This is support for the theory of variation in corona layers 
being the cause of the differences in the distribution patterns of the 200 nm carboxylate-
modified particles. If there was only an effect of the gel structure, the same aggregation 
patterns should have been seen in both types of nanoparticles, which they are not. 
 
There is a small difference in the intensity of the images of the 200 nm PEGylated particles, 
which is due to small differences in the setting of the detector gain and amplifier offset of the 
measurement.   
 
3.1.2	  Distribution	  of	  nanoparticles	  on	  top	  of	  mucus	  
 
The distribution of nanoparticles on top of PSIM and biosimilar mucus was investigated to get 
an idea of how the size and charge of nanoparticles affected the distribution and absorption of 
nanoparticles on the mucus surface. An illustration of the concept is presented in Figure 3.6 
where 1 µm carboxylate-modified nanoparticles settles on the surface of an agar gel. Due to 
the large size of the nanoparticles it was expected to see a migration front of nanoparticles, 
which would accumulates on the gel surface without being absorbed.  
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Figure 3.6 XZ confocal image of the distribution of 0.1% 1 µm carboxylate-modified nanoparticles on 
top of a 5 % (w/v) agar gel. A gradient of the nanoparticles is clearly seen, where the nanoparticles 
accumulate on the agar surface, unable to penetrate the agar gel.  
 
 The average mesh spacing of mucus has been suggested to be 10-200 nm, but properly 
coated particles up to 500 nm has been reported to diffuse rapidly through mucus (Lai et al., 
2007).  Therefore it was expected to see some penetration/adsorption of the 100 nm sized and 
200 nm sized nanoparticles on top of the mucus layers. 
 
Biosimilar mucus and PSIM were added in glass chambers, nanoparticles applied on top, and 
the distribution of the nanoparticles on top of and into the mucus visualized by confocal 
microscopy.  
 
3.1.2.1	  Mucus	  displacement	  
 
The experimental set-up was early on challenged by instant displacement of the mucus layer 
upon addition of the nanoparticle solution, in particular for the biosimilar mucus. Different 
methods like putting the pipette tip against the glass chamber wall, pipetting very carefully 
and using the 5-50 µL pipette to make the droplets smaller were attempted, but independent 
 44 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
of the way the nanoparticle solution were added, the drops moved the 1.25 mm thick mucus 
layer into the corners of the glass chamber, as illustrated in Figure 3.7.  
 
 
Figure 3.7 An eight chambered glass slide filled with 0.10 grams of biosimilar mucus in each 
chamber. For illustration, 100 µL MQ-water has been carefully pipetted into each of the chambers in 
various ways. The mucus layer is displaced by the addition of water, marked by blue arrows. The 
yellow arrows mark areas where the mucus layer is still intact. 
Putting the glass chambers in the freezer after addition of mucus solved the displacement 
problem. The nanoparticles were instantly added to the frozen mucus after retrieving the glass 
chambers from the freezer. Mucus in chambers with newly added nanoparticle solutions is 
depicted in Figure 3.8. 
 
 
      
Figure 3.8 Side view of glass chambers containing different 0.1% (w/v) nanoparticle solutions on top 
of 0.1 g biosimilar mucus (left) and 0.1 g PSIM (right). The pictures were captured straight after 
addition of nanoparticles. 
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3.1.2.2	  Finding	  the	  nanoparticles	  in	  top	  of	  the	  mucus	  
 
The mucus layer was calculated to be ~1.25 mm thick (see Appendix B.2). The chosen 
objective of the confocal microscopy was a water objective with magnification 40 x, and a 
numeric aperture of 0.8. This objective had the greatest working distance of the objectives 
available with this magnification, 1.7 mm, and was able to visualize the whole height/z-
direction of the mucus sample and ~ half of the nanoparticle solution on top of it. However, 
nanoparticles on top of the mucus were not found because the laser had problems penetrating 
the mucus layers. As already indicated by the distribution experiments of nanoparticles in 
mucus, both the biosimilar mucus, and particularly the PSIM, were hard to penetrate for the 
laser light. The XZ images of the nanoparticles mixed into the two mucous systems (Figure 
3.3) clearly displayed a light gradient from the bottom of the glass chambers to the top, where 
the laser could not reach the nanoparticles of the higher mucus layers. Increasing the strength 
of the laser, enabling it to penetrate further through the mucus layers, was not an option, 
because both the mucous systems spread the laser light to a great extent, which resulted in a 
lot of unwanted noise in the confocal images. 
 
Some experiments with thinner mucus layers were conducted, but minor perturbations caused 
the mucus layers to be displaced by the nanoparticle solutions. Thinner mucus layers were 
rejected as a possible option because they were not robust enough for the experimental 
conditions.  
 
During experiments it was observed that the nanoparticle solutions slowly started to dissolve 
the mucus, making it swell from the top, see Figure 3.9.  
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Figure 3.9 Top view of a glass chamber containing 100 µL 1 % 200 nm carboxylate-modified 
nanoparticles on top of 0.10 g biosimilar mucus. The picture is captured a couple of hours after the 
nanoparticle solution was added to the mucus, when the nanoparticle solution had started to dissolved 
the mucus and displace it, making the nanoparticles distribute in a random manner in the mucus. 
 
This was in particular prominent in the biosimilar mucus. The driving force behind this 
phenomenon may be difference in the strength of the ions between the mucus matrix and the 
nanoparticle solutions. A small experiment where performed to confirm how the ion 
concentration of water is affecting the distribution of water on top of mucus. 0.10 g of 
biosimilar mucus and PSIM were put in four glass chambers each, and MQ-water and NaCl-
water of differing concentrations (150 mM, 250 mM, 350 mM) was put on top. The glass 
slide was left for 24 hours and checked for any gradients in the water. The wells with PSIM in 
the bottom had the same appearance; no differences could be seen between the four wells. 
The wells with biosimilar mucus in the bottom had a very weak gradient of more dissolved 
mucus in the well with highest NaCl concentration contra the MQ-water. This means that it is 
probably not the difference in the ion concentration that is the driving force behind the 
dissolution of the mucus by the nanoparticle solutions because the nanoparticle solutions do 
not have a very high ion concentration compared to the biosimilar mucus which contains 10 
mM HEPES buffer with 1.3 mM CaCl2, 1 mM MgSO4 and 137 mM NaCl. The dissolution of 
biosimilar mucus by the nanoparticle solution is probably due to other mechanisms than a 
difference in ion concentration.  
  
After addition of nanoparticles, the mucus layer became more sensitive towards small 
perturbations with time, which was very inconvenient with the experimental conditions. The 
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nanoparticle solution would eventually displace the mucus layer and/or dissolve the top layers 
of the mucus, which made the nanoparticles distribute in a random manner in the mucus, see 
Figure 3.9 and Figure 3.10. Without a stabile mucus layer below the nanoparticles it was 
impossible to study how the nanoparticles distributed on top of, and down in the mucus. 
 
 
Figure 3.10 Bottom view of a glass chamber containing different nanoparticles (1 % (w/v)) on top of 
0.10 g PSIM (top row) and 0.1 g biosimilar mucus (bottom row). The picture is captured after 
experiments, ~3 hours after addition of nanoparticles. The picture illustrates the problems of the 
nanoparticle solutions dissolving and displacing the mucus layer of each well, making the 
nanoparticles distribute in a random manner in the mucus. This was seen to a greater extent in the 
biosimilar mucus than the PSIM.  
During the confocal microscopy sessions, nanoparticles were found in the bottom part of the 
mucus, and these images do not represent what was expected to be found, see Figure 3.6. Two 
of the images presented in Figure 3.11 illustrate the appearance of the nanoparticles visualized 
by the laser.  
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Figure 3.11 Confocal images in the XY, XZ and YZ direction of 0.1 g PSIM (top row) and 0.1 g 
biosimilar mucus (bottom row), were 100 µL 0.1 % (w/v) 1 µm carboxylate-modified nanoparticles 
were applied to the top of the mucus layers. 
 
3.1.2.3	  Control	  measurements	  
 
In order to test if the method works better with another mucous matrix, purified pig gastric 
mucins were dissolved in physiological NaCl water to concentration of 5 % (w/v), and 0.10 g 
of the gel was added to a glass chamber prior to freezing. 1 µm carboxylate-modified 
nanoparticles (0.1% (w/v)) were gently placed on top and visualized by confocal microscopy. 
It was expected to find the nanoparticles on top of the gel layer, as the large size prevents 
them from being absorbed. Also the gel was close to transparent, which the confocal laser 
were penetrate with ease. The results are presented in Figure 3.12. 
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Figure 3.12 XZ and YZ confocal images of 100 µL 0.1 % 1 µm carboxylate-modified nanoparticles 
put on top of 0.10 g 5 % (W/V) pig gastric mucin matrix. The nanoparticles were found in channels 
and holes in the matrix near the bottom of the glass chamber.  
As expected were the pig gastric mucin matrix easily penetrated by the laser because of the 
transparent gel. However, as soon as the frozen sample was thawed, the nanoparticle solution 
started to dissolve the pig gastric mucin gel. When visualizing the nanoparticles by confocal 
microscopy, the nanoparticles were found at the bottom of the glass chamber. The PGM 
matrix, just like biosimilar mucus and PSIM, were not robust enough for the experimental 
conditions, but was easily penetrated by the laser.  
 
3.1.3	  Conclusive	  remarks	  on	  the	  distribution	  experiments	  
 
The results of the distribution experiments were the nanoparticles were mixed into PSIM and 
biosimilar mucus, showed no characteristic trends in the distribution patterns of nanoparticles, 
which could be related to the size and/or charge of the nanoparticles. The negatively charged 
particles formed somewhat larger aggregates than the positively charged particles, but 
aggregate formation was seen for all the particles. Based on these data it will not be possible 
to predict the distribution pattern of other nanoparticles. The distribution patterns of the 
nanoparticles in biosimilar mucus were quite similar to the distribution patterns observed in 
PSIM; no large aggregates, which would make it impossible for cells to absorb the 
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nanoparticles, were formed. This is good news for the utilization of biosimilar mucus in drug 
absorption studies in combination with Caco-2 cells.  
 
The method of adding nanoparticles on the top of mucus and visualizing the distribution with 
confocal microscopy is valid, proven by the 1 µm carboxylate-modified nanoparticles put on 
top of agar (Figure 3.6). The PSIM and biosimilar mucus was not suitable for this type of 
experiments mainly due to two things; the laser of the confocal microscopy had problems 
penetrating the mucus matrixes, the PSIM in particular. Neither of the matrices was robust 
enough for the experimental conditions, which resulted in a random distribution of the 
nanoparticles in the XYZ plane of the mucus. This was especially prominent in the biosimilar 
mucus. It can be argued that in a nanoparticle drug delivery study the biosimilar mucus will 
be more stable when put on top of Caco-2 cells, compared to the stability seen in the glass 
chambers. The Caco-2 cells have a glycocalyx (Lochner et.al, 2003), which interacts with the 
mucus and may stabilize it. This would create a more stable mucus surface, and give better 
mucus attachment to the surface. However, this does not mean that similar artefacts as 
observed in the distribution experiments might not be observed if biosimilar mucus is utilized 
in nanoparticle drug absorption studies. If so, it would probably be a source of false results, 
and researchers working with biosimilar mucus in absorption studies should be aware of this. 
 
What is important to have in mind when investigating confocal images like the ones presented 
in this section is that the discussion and conclusions are based on qualitative data. The images 
in the figures are a representative selection, but might not reveal all the details regarding 
nanoparticle distribution, and one should be careful to make generalized conclusions based on 
these data. 
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3.2	  Development	  of	  the	  plate	  method	  
 
The majority of nanoparticles entering the small intestines undergo direct transit and 
elimination through the faeces. In order to avoid direct elimination of nanoparticle drug 
delivery systems (NDDS), the nanoparticles has to interact at the mucus surface, which would 
result in a prolonged residence time at the site of adsorption and/or increase the drug 
concentration gradient over the mucus layer. An interaction of NDDS at the mucus surface 
requires that the particles have mucoadhesive properties. It is also crucial for the NDDS not to 
adhere too well to the mucus, which might restrict the absorption of the nanoparticles (Lai et 
al., 2009a) (Ponchel and Irache, 1998). 
 
More knowledge and information regarding mucoadhesion is still needed for effective 
delivery of NDDS over the mucus barrier in the intestines. The objective of developing the 
plate method was to find a high throughput method of characterizing the adhesion of 
nanoparticles in mucus and how different variables might affect the mucoadhesion of various 
nanoparticles. The method is an attempt to mimic the in vivo situation.  
 
3.2.1	  The	  plate	  method	  	  
 
The basic idea behind the plate method is to coat the wells of microtiter plates with mucus by 
adding an appropriate amount of mucus and letting it partially dry. Fresh mucus is not stable 
enough for the subsequent steps of the method, but will stabilize sufficiently when it dries to a 
certain amount. Fluorescent nanoparticles are added, and within a given time frame removed. 
The last step of the method is to gently wash off particles that have not attached to the mucus, 
followed by fluorescence intensity measurements of the adhered particles. The fluorescence 
should then be directly correlated to the adhesion of nanoparticles on the mucus. The main 
steps of the method are illustrated in Figure 3.13. Furthermore, the effect of variations in 
variables like pH and osmolality, addition of bile sales, intestinal fluid etc. would be able to 
be tested on the mucoadhesion of nanoparticles. 
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A plate-based system gives a high throughput screening, and can simultaneously test many 
different nanoparticles and variables that might influence the adhesion of the nanoparticles. 
The system would also be able to handle several replicates at the same time, making the test 
system very efficient. 
 
 
Figure 3.13 The main steps of the plate method for characterizing the adhesion of nanoparticles to 
mucus. Mucus is added to a microtirer well and left to dry to coat the bottom of the well. A 
nanoparticle solution of fluorescent nanoparticles are added, and removed within a given time frame. 
An additional washing procedure makes sure that the particles that have not adhered to the mucus are 
removed. Fluorescence intensity measurements of the adhered nanoparticles would then directly 
correlate to the amount of nanoparticles that adhered to the mucus surface. 
 
The process of developing the new plate method can be divided in two distinct phases; (i) the 
optimization phase, which includes experimentation and optimization of different conditions 
regarding the applicability of the method, and (ii) the test phase, with fluorescence 
measurements of nanoparticle mucoadhesion under varying conditions and variables. 
 
3.2.2	  The	  Optimization	  process	  
 
It was determined to start the optimization process using biosimilar mucus, and later include 
the PSIM into the experiments. The biosimilar mucus was preferred to the PSIM, as it is a 
more homogenous system, and can easily be produced in the laboratory. 
 
The first challenge was the amount of mucus each well should contain, and how long and by 
which method the drying should be done. Especially three criteria had to be met in order to 
optimize these variables; (i) the drying time and method should leave the mucus surface 
looking even and moist without any cracks, (ii) the mucus should be homogenously dried, 
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without pellicle formation, and (iii) after drying the mucus has to be stable enough to enable 
the nanoparticle solution to be lightly knocked out of the microtitrer plate wells without 
mucus also becoming dislodged. 
 
3.2.2.1	  Determining	  the	  time	  of	  drying	  and	  the	  correct	  drying	  method	  
 
Prior to, and after addition of mucus in the wells, the microtitrer plates were weighed so that 
the total amount of mucus added and percentage mucus to be evaporated could be determined. 
The mucus was added in each well by pipetting with a cut off pipette tip, since the narrow tip 
complicated the aspiration of the viscous mucus into the pipette tip. Because pipetting a 
viscous gel like biosimilar mucus with a shortened tip is not a very appropriate approach, the 
mucus applied in each well were weighed out, with the assumption that the weight of 100 µL 
of mucus were 0.10 g. 
 
The approach to determine how long the mucus should dry was to add a given amount of 
mucus in 8 wells of a microtitrer plate and leave it to dry on the lab bench in a humidity and 
temperature regulated laboratory. When the mucus had dried an appropriate amount of time 
so that the surface was moist and even without any cracks, the stability of the mucus was 
tested. First the plate were turned 90 ° and movement of the mucus were observed. If the 
mucus allowed for it, the plate were turned 180 ° and given some gentle knocks to see if the 
mucus were dislodged onto a sheet of paper or was dry enough to stick to the well walls 
without exposing the well bottom. Dislodged mucus on a sheet of paper is illustrated in Figure 
3.14 (left). If the mucus had dried enough to stand this “stability testing”, the stability with 
addition of water were tested. 100 µL MQ-water were added to one well at the time, where 
the water of the first well were allowed to stay in the well for 1 minute before it was gently 
knocked out, onto a sheet of paper. The sheet of paper was then examined for traces of mucus. 
No mucus traces on the sheet of paper were positive results. This technique were repeated 
with the remaining mucus coated wells, where the water was allowed to stay in the well for 2 
minutes, 3 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes.  Figure 
3.14 (right) illustrates the appearance of the sheet of paper after the stability testing with 
water. In addition to testing the stability of the mucus, this method also indicated how long 
the nanoparticle solutions could reside on top of the mucus before it would be completely 
absorbed by the dried mucus, which was not desirable. 
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Figure 3.14 To the left a picture of the dislodging of mucus (red ring) from the wells of the microtitrer 
plates, before the addition of water. To the right an example of how the sheet of paper might appear 
after the stability testing. The initial wet spots from the water are traced with a blue pen. The wet spots 
were checked for traces of mucus. 
 
The method of drying and stability testing the mucus were repeated with various amounts of 
mucus and time frames. As the 96 well microtitrer plates utilized had wells where the 
recommended working volume were 350 µL (VWR International, 2014) mucus volumes of 
400 µL, 200 µL and 100 µL were looked at as possible appropriate volumes with the fact that 
the volume of the mucus would shrink during drying, in mind. The drying times tested ranged 
from 5 hours up to 70 hours, and the time and initial amount of mucus in the wells were 
optimized. 
 
After several experiments with 100 µL, 200 µL or 400 µL mucus in each microtitrer plate 
well, the optimal amount was found to be 200 µL. When using 400 µL mucus in each well, 
the time to dry the mucus was very long, and a lot of mucus ended up stuck to the well walls 
and sometimes cracked, see Figure 3.15. This was not ideal upon addition of water, where the 
dried mucus on the walls would very easily absorb the water and slide down the walls and on 
top of the dried mucus surface. When using 100 µL of mucus in each well the drying time 
was the lowest, but the meniscus the mucus created was in general quite steep, and with this 
small amount of mucus in the well, the bottom layer of the mucus ended up being very thin 
and dry compared to the mucus comprising the meniscus. With 200 µL in each well, the “wall 
effect” were minimized and the cracked up mucus seen in the wall wells with 400 µL were 
also markedly reduced, see Figure  3.16. 
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Figure 3.15 The appearance of mucus after drying on the lab bench, when applying 400 µL biosimilar 
mucus in each well. The arrows point to the mucus that are left in the walls of the wells, the dried 
mucus in the bottom of the wells, and highlights an artefact seen; light reflection in the mucus. 
 
 
 
Figure 3.16 The appearance of 200 µL newly added biosimilar mucus to wells (left) and the 
appearance of the same mucus after drying on the lab bench in a temperature and humidity regulated 
laboratory for ~30 hours. The “white spots” in each well is a light reflection artefact. 
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When drying the mucus on the lab bench, the optimized time was found to be ~30 hours for 
the wells containing 200 µL biosimilar mucus. After replicate experiments, the weight to 
evaporate from the mucus was found to be 65-70 %, so that only 30-35 % of the start weight 
of mucus remained in the wells (calculations in Appendix C.1). At this point the mucus 
surface was smooth and moist (see Figure 3.16), and the mucus “passed” the stability tests. 
 
As mentioned, the stability testing of mucus with water also gave indications of how long the 
nanoparticle solution can reside on top of the mucus surface without affecting it. The dried 
mucus was expected to absorb water, but if all the water of the nanoparticle solutions were 
absorbed, the nanoparticles would not be able to be removed from the mucus surface. There 
was a clear distinction in appearance of the mucus surface and especially the mucus near and 
on the walls after water had been added in the wells for 5 minutes and 10 minutes. After the 
water had been on the mucus surface for 10 minutes the driest mucus on the walls had 
absorbed a lot of water, and started to slide down the wall wells. This trend became more 
pronounced the longer the water resided in the wells. After 5 minutes or less this trend could 
not be seen, which lead to the assumption that the nanoparticles were to be added and 
removed from the mucus surface within five minutes during the actual fluorescence 
measurements. This trend could also be seen on the paper sheet the water was knocked onto. 
The amount of water to end up on the sheet was considerably greater after the water had 
resided on the dried mucus for 5 minutes, than 10 minutes or longer, indicating more water 
absorption at 10 minutes than 5 minutes. 
 
As an attempt to find an alternate and more time efficient drying method, different amounts of 
mucus were attempted to be dried in a heating cabinet holding 50 °C. The mucus surface was 
examined and the mucus stability tested. The drying cabinet method resulted in an 
inhomogeneous drying of the mucus with pellicle formation, and this technique was rejected 
in favour of the drying of mucus on the lab bench, which gave homogeneous drying results. 
These results indicated that the drying of the mucus should not take place too quickly. 
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3.2.2.2	  Determining	  the	  amount	  and	  concentration	  of	  nanoparticles	  
 
After determining the optimal amount of mucus, the best drying method and time, 
optimization regarding the nanoparticles was carried out. 
 
The first thing looked at was the volume of nanoparticles that should be added in each well. 
The nanoparticle volume should with ease coat the entire mucus layer. By pipetting MQ-
water in the amounts 25 µL, 50 µL, 60 µL, 75 µL and 100 µL into empty wells, the ability of 
the water to cover the bottom of the well was evaluated. This was replicated with wells 
containing dried mucus, because of different surface properties of the empty wells and the 
dried mucus. The water spread with more ease in the wells with mucus coating the bottom, 
and the determined required amount of liquid to coat the mucus were ≧ 75 µL. It was 
assumed that the nanoparticle solutions would spread in approximately the same manner as 
the water, i.e. have contact angles not far from the MQ-water.  
 
Dilution series of nanoparticles with minimum concentration 0.0000001 % (w/v) and a 
maximum concentration of 0.01 % (w/v) of the fluorescent nanoparticles FluoSpheres® 200 
nm carboxylate-modified yellow-green and 200 nm carboxylate-modified red were made, and 
a standard curve of the fluorescence intensity of each of the dilution series were plotted, see 
Figure 3.17. The standard curve could then later be interpolated to calculate the amount of 
particles that still adhered to the mucus after the particle removal and washing step of the 
plate method. The fluorescence of the nanoparticle dilution series was measured in microtitrer 
plates with no mucus coating in the bottom of the wells. 
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Figure 3.17 Standard curves of the FluoSpheres® yellow-green (left) and red (right), made with 
average values of three replicates. The ex./em. wave-lengths of the measurements were 495/535 nm 
for the yellow-green particles, and 580/615 nm for the red particles. The volume of nanoparticle 
solution in each well was 100 µL. 
 
The fluorescence measurements of the dilution series of yellow-green and red FluoSpheres® 
 (Figure 3.17) revealed that the lowest concentration of nanoparticles detected by the plate 
reader were 0.000002 % (w/v). When the highest concentration of the nanoparticle dilutions 
was 0.01 %, the standard curves were still within the linear region.  
  
To investigate if the plate reader measures the fluorescence based on the amount of particles 
in a solution or the concentration of nanoparticles, two dilution series of yellow-green 
FluoSpheres® were made. The amount of nanoparticles of sample one of dilution series 
number one was calculated to be the same as sample one of the second dilution series etc., but 
with differing concentrations. The volume of the solutions in dilution series one was 100 µL, 
and the volume of the solutions in the second dilution series was 200 µL. The dilution series 
are given in Table 3.2, and the results of the fluorescence intensity measurements are 
presented in Figure 3.18. 
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Table 3.2 The dilution series of yellow-green FluoSpheres® used to determine if the plate reader 
measures the fluorescence intensity based on the amount of nanoparticles in a solution or the 
concentration of nanoparticles in a solution. The two solutions of each row, contains the same amount 
of nanoparticles. 
Dilution series #1: 100 µL nanoparticle 
solutions with concentration (% (w/v)) 
Dilution series #2: 200 µL nanoparticle 
solutions with concentration (% (w/v)) 
0.0001 0.00005 
0.00004 0.00002 
0.00001 0.000005 
0.000004 0.000002 
0.000001 0.000005 
 
  
 
Figure 3.18 Two dilution series of nanoparticles were the number of nanoparticles of the solutions in 
dilution series one, matches the number of nanoparticles in dilution series two, but has differing 
concentrations. In the plot to the left the measured fluorescence intensity is plotted against the number 
of particles in the 100 µL solutions and the 200 µL solutions. In the plot to the right the fluorescence 
intensity is plotted against the concentration of the 100 µL solutions and the 200 µL solutions.  
 
From Figure 3.18 it is seen that the graphs plotting the amount of nanoparticles of each 
solution in the two dilution series overlap, and that the graphs plotting the concentration of the 
two dilution series do not overlap. This shows that the plate reader measures the fluorescence 
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based on the amount of fluorescent particles in the solution, not the concentration of the 
solution.  
 
3.2.3	  Background	  fluorescence	  	  
 
Early experiments of fluorescence intensity measurements of nanoparticles on top of dried 
biosimilar mucus gave high fluorescence (data not included for early measurements), leading 
to the examination of the background fluorescence of biosimilar mucus. Fluorescence 
intensity measurements were conducted on eight replicates of fresh biosimilar mucus, dried 
bioismilar mucus and dried biosimilar mucus with 100 µL MQ-water on top. The results of 
the measurements are presented in Figure 3.19 and can be found as a table in Appendix C.2. 
 
  
Figure 3.19 Background fluorescence intensity measurements of different conditions of 
biosimilar mucus; 200 µL mucus dried for ~30 hours, 200 µL mucus dried for ~30 hours then 
added 100 µL MQ-water and 200 µL fresh mucus. For each of the mucus conditions, eight 
replicates were measured. The ex./em. wavelengths of the plate reader were set to the 
wavelength used to measure the yellow-green FluoSpheres®; 495/535 nm. 
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From the results presented in Figure 3.19 it was obvious that the biosimilar mucus gave high 
background fluorescence, which was dependent on the condition of the mucus; whether it was 
dried or not. It was considered to drop the utilization of biosimilar mucus, and continue the 
development of the method with PSIM, but it would have to be verified that PSIM did not 
give any background fluorescence first. 
 
Little or no background fluorescence were seen in the distribution experiments (see Figure 
3.3), which gave no reason to believe that biosimilar mucus or PSIM would give off any 
background fluorescence. However, it was also seen that both the PSIM and biosimilar mucus 
spread the laser light of the confocal microscopy to a great extent. It could not be ruled out 
that the plate reader might have detected some form of wavelengths, which not necessarily 
were fluorescence. Therefore a more thorough investigation of the background fluorescence 
of both PSIM and biosimilar mucus was performed. 
 
New control background fluorescence measurement were performed on eight replicates of 
fresh biosimilar mucus, fresh PSIM, 5 % (w/v) Sigma mucin solution, 0.00001 % (w/v) 
yellow-green FluoSpheres®, 0.00001 % (w/v) red FluoSpheres®, MQ-water and empty 
wells. All the volumes were 200 µL. The fluorescence of 5 % (w/v) Sigma mucin solution 
was measured to check whether the Sigma mucin was responsible for the high background 
fluorescence of the biosimilar mucus. The MQ-water and empty wells were zero controls. The 
choice of the low concentration of the FluoSpheres® were made with the assumption that it 
would mimic the amounts of nanoparticles to be found on the mucus surface after the 
nanoparticle removal and washing step of the plate method. The fluorescence intensity 
measurements were performed twice; with the ex./em. wavelengths corresponding to 
excitation of the yellow-green FluoSpheres® - 495/535 nm, from now on referred to as 
yellow-green wavelengths - and the ex./em. wavelengths corresponding to the excitation of 
the red FluoSpheres® – 580/615 nm, from now on referred to as red wavelengths. The results 
of the background fluorescence measurements are presented in Figure 3.20. The same results 
are presented in Table 3.3 and Table 3.4 for a more precise illustration.  
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Figure 3.20 Fluorescence intensity measurements of eight replicates of fresh biosimilar mucus, fresh 
PSIM, 5% (w/v) Sigma solution, yellow-green FluoSpheres® (0.00001% (w/v)), red FluoSpheres® 
(0.00001% (w/v), MQ-water and empty wells. The upper plot is fluorescence measurements 
performed with ex./em. wave-lengths of the yellow-green FluoSpheres® (495/535 nm) and the lower 
plot is performed with ex./em. wave-lengths of the red FluoSpheres® (580-615 nm). The volume of 
sample in each well was 200 µL. 
 63 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
Table 3.3 Fluorescence intensity measurements of eight replicates of fresh biosimilar mucus, fresh 
PSIM, 5% (w/v) Sigma solution, yellow-green FluoSpheres® (0.00001% (w/v)), red FluoSpheres® 
(0.00001% (w/v)), MQ-water and empty wells. The fluorescence measurements are performed with 
ex./em. wave-lengths of the yellow-green FluoSpheres® (495/535 nm), and with 200 µL sample in 
each well. The values of the bottom row are average values of the eight replicate measurements. 
Empty MQ- 
water 
Sigma 
mucin 
5% 
Biosimilar 
mucus 
PSIM yellow-green 
(0.00001 %) 
red 
(0.00001 
%) 
19 23 29931 34341 42203 720 30 
20 35 30925 34130 44247 772 35 
17 25 32316 33301 44072 744 27 
14 20 32351 32002 41968 753 25 
28 28 31176 33071 38598 788 25 
19 26 33160 33362 36118 754 33 
18 28 31106 33055 40798 661 21 
26 25 32470 31349 41599 741 30 
20.13 26.25 31679.38 33076.38 41200.38 741.63 28.25 
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Table 3.4 Fluorescence intensity measurements of eight replicates of fresh biosimilar mucus, fresh 
PSIM, 5% (w/v) Sigma solution, yellow-green FluoSpheres® (0.00001% (w/v)) , red FluoSpheres® 
(0.00001% (w/v)), MQ-water and empty wells. The fluorescence measurements are performed with 
ex./em. wave-lengths of the red FluoSpheres® (580-615 nm), and with 200 µL sample in each well. 
The values of the bottom row are average values of the eight replicate measurements. 
Empty MQ- 
water 
Sigma 
mucin 
5% 
Biosimilar 
mucus 
PSIM yellow-green 
(0.00001 %) 
red 
(0.00001 %) 
43 53 11416 15200 38147 60 1958 
24 55 12227 15320 45391 40 1889 
28 45 12640 14751 38857 47 1923 
20 45 12493 13900 39883 46 1693 
63 51 12734 14082 28449 24 1956 
28 36 13277 14713 24116 51 2104 
46 45 12385 14682 32205 43 1929 
58 33 13581 13492 30300 55 2090 
38.75 45.38 12594.13 14517.50 34668.50 47.75 1942.80 
 
 
The results presented in Figure 3.20 , Table 3.3 and Table 3.4 show that the biosimilar mucus, 
5 % (w/v) Sigma mucin solution and the PSIM have high average background fluorescence 
values compared to the FluoSpheres®. 
 
The highest fluorescence intensity was quite unexpectedly detected in the PSIM samples. 
Auto fluorescence does occur in nature, but is most common in bacteria, algae, some insects, 
moths and aquatic invertebrates. Native mucus form pig intestines is not expected to exhibit 
much auto fluorescence (Heredia et al., 2008). However, the detection of high background 
fluorescence might be connected to the great light scattering of the confocal laser seen in the 
nanoparticle distribution experiments. A plausible explanation for the high background 
fluorescence in the PSIM, biosimilar mucus and the Sigma mucin 5% (w/v) solution might be 
that the detector of the plate reader has detected Raman scattering. When a light beam 
interacts with a material, part of the light is reflected, part of it is transmitted and part of it 
scattered. When the scattered light has different wavelengths than the incoming light, the 
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scattered light is called Raman scattering, and is a sort of inelastic scattering (Washington 
University in St.Louis Department of Earth and Planetary Sciences, 2014). This type of 
scattering can be detected by the detectors of plate readers and other scientific instruments, 
and would in this case give the impression of high background fluorescence of the PSIM, 
biosimilar mucus and Sigma mucin. Another plausible reason for the detection of high 
background fluorescence in the PSIM might be that the pig was feed food that contained 
fluorescent components or had fluorescent bacteria in the intestines, contaminating the 
samples. The mucus of the intestines was not rinsed after extraction from the intestines, and 
debris was visible. However, the most plausible explanation is the occurrence of Raman 
scattering, supported by the fact that the laser light of the confocal microscopy was spread to 
a great extent. 
 
The average values of the fluorescence intensity of all the systems tested were higher when 
exposed to the green wavelengths than the red wavelengths, which indicates that whatever is 
causing the detected fluorescence, it is sensitive to the ex./em. wavelength settings of the 
measurement. With the exception of the yellow-green FluoSpheres®, this was not expected. 
As no particular background fluorescence was detected in the distribution studies, it was not 
expected to see any background fluorescence in the PSIM and biosimilar mucus when excited 
by the xenon lamp of the plate reader in the first place. There was no reason to believe that the 
fluorescence intensity measured in the mucus samples were true fluorescence, and that it 
would be sensitive to the ex./em. wavelengths of the measurement. The trend was also seen in 
the zero controls, which is particularly hard to explain. The FluoroNunc plates utilized are 
specially designed for fluorescence measurements, and it is not clear why the trend is 
observed in the controls also.  
 
The fluorescence intensity measured in the biosimilar mucus and the Sigma mucin 5 % (w/v) 
solution was quite similar, with the biosimilar mucus having fairly higher values in both the 
measurements. This confirmed the Sigma mucin to considerably contribute to the 
fluorescence intensity detected in the biosimilar mucus. 
 
One of the most important results of the background fluorescence measurements were that the 
variation in fluorescence intensity between biosimilar mucus replicates are greater than the 
fluorescence measured in the nanoparticle solutions. This renders it impossible to solve the 
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background fluorescence problem by subtracting the background fluorescence of dried mucus 
from the actual measurements of adsorbed nanoparticles on dried mucus. It might be argued 
that the concentration of the nanoparticles should have been raised, but a very high 
concentration of nanoparticles would most likely not have represented the amount of particles 
expected to adhere to the surface of the mucus after the removal of the nanoparticles and the 
washing step of the plate method. 
 
3.2.3.1	  Control	  background	  fluorescence	  measurements	  
 
For a more thorough examination of the background fluorescence of the various mucous 
systems, additional and some replicative fluorescence measurements were conducted, see 
Figure 3.21 and Appendix C.2.2. 
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Figure 3.21 Additional background fluorescence intensity measurements. The upper row presents 
measurements of empty wells, MQ-water, dried biosimilar mucus (BSM), dried biosimilar mucus with 
MQ-water on top, fresh biosimilar mucus, dried PSIM, 5 % (w/v) Sigma mucin solution, yellow-green 
FluoSpheres® (0.00001% (w/v)) and red Fluospheres® (0.00001% (w/v)).  The upper row results are 
measured with ex./em. wavelengths of 495/535 nm (left) and 580/615 nm (right). The lower row 
presents fluorescence intensity measurements of empty wells, MQ-water, 5 % (w/v) Sigma mucin 
solutions, fresh biosimilar mucus, fresh native small intestinal mucus, yellow-green FluoSpheres® 
(0.00001 % (w/v)) and red Fluospheres® (0.00001 % (w/v)). The results in the lower row are 
measured with ex./em. wavelengths of 505/545 nm (left) and 580/625 nm (right). All volumes were 
200 µL. 
 
From the additional background fluorescence measurements presented in Figure 3.21 it was 
verified that the PSIM, biosimilar mucus and Sigma mucin 5 % (w/v) solutions has differing 
amounts of fluorescence intensity dependent on the ex./em. wavelengths of the measurements. 
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This was verified when getting slightly different fluorescence intensity results after 
replicating the measurement presented in Figure 3.20 with somewhat different ex./em. 
wavelengths than the yellow-green and red wavelength of the earlier measurements (lower 
row of Figure 3.21). The new measurements of dried biosimilar mucus, dried biosimilar 
mucus with MQ-water and fresh biosimilar mucus (upper row of Figure 3.21) showed the 
opposite trends as the previous measurement (Figure 3.19), with the highest fluorescence 
intensity detected in the fresh biosimilar mucus. However, the values are still very high. 
Although there was seen some variation in the fluorescence intensity when comparing the 
additional measurements to the first ones, the trends were concurrent with a very high 
fluorescence intensity detected in both the PSIM and biosimilar mucus samples, both fresh 
and dry. 
 
3.2.3.2	  Sigma	  mucin	  gradient	  experiment	  
 
The fluorescence intensity of Sigma mucin was tested for concentration dependency to verify 
that the fluorescence detected was a real effect of the Sigma mucin. A dilution series of Sigma 
mucin solved in MQ-water were made, with concentrations 0.05 % (w/v), 0.1 % (w/v), 0.5 % 
(w/v), 1 % (w/v) and 5 % (w/v). The fluorescence intensity of 200 µL of each dilution was 
measured with yellow-green wavelengths and red wavelengths. The results from the 
measurements with the yellow-green wavelengths are presented in Figure 3.22, the remainder 
of the data is to be found in Appendix C.2.3. 
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Figure 3.22 Fluorescent intensity measurements of three replicates of different concentrations of 
Sigma mucin solutions. The ex./em. wave-length of the measurements were 495/535 nm. The volume 
of the solutions was 200 µL. In the left plot: The percentages represent the concentration % (w/v) of 
the different solutions. Empty wells and MQ-water filled wells were also measured as control. 
As seen in the results of Figure 3.22 there is a clear correlation between the concentration of 
Sigma mucin and the intensity of the fluorescence measured. It is a linear dose response 
relationship between the concentration of the Sigma mucin solutions and the fluorescence 
intensity.  
 
3.2.3.3	  Measuring	   the	   fluorescence	   of	   differing	   amounts	   of	   biosimilar	  mucus	  
and	  PSIM	  
 
The fluorescence intensity of 100 µL and 200 µL fresh biosimilar mucus and fresh PSIM was 
measured to investigate the correlation between the amount of mucus and the intensity of the 
fluorescence. The measurements were conducted twice, with yellow-green and red ex./em. 
wavelengths. The results from the measurements of yellow-green wavelengths are presented 
in Figure 3.23 and the remaining measurements can be found in Appendix C.2.4. 
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Figure 3.23 Fluorescence intensity measurements of different amounts of biosimilar mucus (BSM) 
and PSIM. The ex./em. wavelength in the measurement were 495/535 nm, and there were eight 
replicates of each amount of mucus. 
Quite unexpected, the fluorescence intensity detected in 100 µL PSIM have almost the same 
values as the fluorescence intensity detected in 200 µL PSIM. It was expected to see a 
doubling of the fluorescence intensity in the 200 µL mucus samples to the 100 µL samples. 
The average values of fluorescence intensity of the 100 µL PSIM samples are actually 
somewhat higher than the average values of the 200 µL PSIM (see Appendix C.2.4). The 
biosimilar mucus measurements show a somewhat more expected trend, as the fluorescence 
of 100 µL biosimilar mucus show lower or the same amount of fluorescence intensity as the 
200 µL wells, although not twice as high.  
 
These results might suggest that the amount of fluorescence detected in 100 µL mucus 
“saturates” the fluorescence intensity possible to detect, so that higher amounts of mucus will 
give off approximately the same values. However, these results might rather indicate that 
there is some sort of surface effect in the mucus. From Figure 3.18 it was determined that the 
plate reader measures the amount of nanoparticles in a solution, and not the concentration of 
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the nanoparticles. In these measurements the xenon lamp of the plate reader had no problems 
reading off the correct fluorescence when there were only nanoparticles in the wells. For the 
measurements presented in Figure 3.23 it might be that the plate reader is not measuring the 
amount of “fluorescent” matter, because of poor penetration of the mucus. This is supported 
by the previous findings of poor laser penetration of the mucus by the confocal microscope 
(see section 3.1.1.2). Due to the xenon lamps’ poor penetration of the mucus, the plate reader 
measures only the “fluorescence” in the surface of the mucus. Hence will the plate reader 
detect broadly the same fluorescence intensity from mucus samples of both 100 µL and 200 
µL. 
 
3.2.4	  Conclusive	  remarks	  on	  the	  plate	  method	  
 
Some of the variation seen in the fluorescent measurements between replicates of the PSIM 
and between replicates of the biosimilar mucus, might be due to the method of weighing the 
correct amount of mucus into each well. This method is not very accurate, but due to the high 
viscosity of the mucus, pipetting of mucus was not possible. However, the experiment that 
measured the fluorescence intensity of 100 µL and 200 µL biosimilar and PSIM samples gave 
results that refute this theory, when it seemingly was no big difference in the fluorescence 
intensity measured between the two amounts of mucus.  
 
As the measurements were wavelength dependent, it might have been possible to find 
wavelengths were the high fluorescence intensity of the biosimilar mucus and PSIM was not 
detected. However, the ex./em. maxima of the yellowgreen (505/515 nm) and red (580/605 
nn) FluoSpheres® restricted the wavelengths of the measurements to these approximate 
regions of the light spectra.  
 
Even though there was seen some variation in the fluorescence intensity between replicate 
experiments, all the fluorescence intensity measurements of the PSIM and biosimilar mucus 
were concurrently high. The high and varying amount of background fluorescence of the 
mucous systems was not feasible with the further development of the plate method. It shall 
not be ruled out that there might be a solution to the problem, but the restricted time of the 
master thesis was also a contributory factor to the decision to terminate the experiment series.  
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All in all the plate method looked promising up until it was detected a high background 
fluorescence intensity in the biosimilar mucus and the PSIM, which most likely is attributed 
to Raman scattering. The Sigma mucin is to a high extent responsible for the fluorescence 
intensity detected in the biosimilar mucus. With the exception of the red FluoSpheres® all the 
other variables tested gave off higher fluorescence intensity values when exposed to the 
yellow-green ex./em. wavelengths than the red ex./em. wavelengths, hence showing 
wavelength dependency. It was decided to terminate the series of experiments, as the results 
were not feasible with the further development of the plate method. 
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3.3	  Rheological	  profiling	  of	  biosimilar	  mucus	  and	  PSIM	  
 
3.3.1	  Rheological	  measurements	  	  
 
Oscillatory rheological measurements were performed on PSIM, biosimilar mucus and 
solutions of Sigma mucin type II. The measurements on biosimilar mucus and PSIM were 
performed to determine that the biosimilar mucus gives a comparable rheological profile and 
viscoelastic properties to the PSIM. The viscoelastic properties of mucus are predominantly a 
function of the mucin matrix (Lai et al., 2009b). The biosimilar mucus contains components 
like lipids, PAA and bovine serum albumin. To verify the necessity of these non-mucin 
components of the biosimilar mucus, control measurements were run on Sigma mucin type II 
dispersed in a 10 mM HEPES buffer containing 1 mM MgSO4 and 1.3 mM CaCl2. Three 
different concentrations of the mucin solutions were prepared and measured, 5 % (w/v) - 
which is the same concentration as in biosimilar mucus, 8 % (w/v) and 10 % (w/v). 
 
Small deformation oscillatory frequency sweeps were chosen, as these measurements are run 
at non-destructive conditions and “best reflects mucus rheology in the native, unperturbed 
way” (Lai et al., 2009b). Also large deformation oscillatory strain sweeps were run in order to 
investigate the rheological reversibility of PSIM and biosimilar mucus. 
 
3.3.2	  Rheological	  measurements	  of	  PSIM	  
3.3.2.1	  Frequency	  sweeps	  
 
Three replicates of strain controlled frequency sweeps in the range 0.001-10 Hertz were run 
on different PSIM samples. Ten minutes prior to the frequency sweeps, strain sweeps were 
run in the stain range 1*10-5-10 to determine the linear viscoelastic region where the 
rheological values are independent of the imposed strain. The time lag allowed for the 
rheological recovery of the mucus gel.  Results from the three replicate frequency sweeps are 
presented in Figure 3.24. 
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Figure 3.24 Frequency sweeps of PSIM in the frequency range 0.001-10 Hertz. The storage (G’) and 
loss moduli (G’’) are presented in the upper plot and the corresponding phase angles are presented in 
the bottom plot. All strains were fixed within the linear viscoelastic region, and run with a constant 
temperature of 25 °C. 
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The three frequency sweeps presented in Figure 3.24 generally display the same trends, with a 
dominant elastic-like behaviour of all the samples over the whole frequency interval. The 
absolute values of the storage moduli (G’) are high compared to the absolute values of the 
loss moduli (G’’). The variation in the absolute storage modulus (G’) values probably reflects 
the natural variation expected to be found between samples of untreated ex vivo PSIM, as 
native mucus is an inhomogeneous material that consists of different amounts of mucins, 
water, ions, lipids, proteins, cell debris, nucleic acids, debris from food etc., that will affect 
the viscoelastic properties of mucus (Girod et al., 1992) (Smart, 2005).  
 
The plots in Figure 3.24 display frequency dependency of the rheological variables as would 
be expected from un treated ex vivo PSIM (Zhong and Daubert, 2013). The different transient 
and non-transient intermolecular interactions that maintain the mucus gel matrix, like 
electrostatic, hydrophobic and H-bonding interactions, have differing lifetimes and relaxation 
times. When the frequency increase there will be less and less time for the rearrangement of 
the transient interactions (Taylor Nordgård and Draget, 2011), which restricts the flow of the 
mucus, and renders it to become more elastic in its’ behaviour as the frequency increase. This 
is reflected as a steep increase in the storage modulus (G’) values seen in the frequency sweep 
of Figure 3.24, and the low values of the phase angles in the bottom plot of Figure 3.24. The 
slight U-shape of the phase angles reflects both the behaviour of the storage moduli (G’), and 
the loss moduli (G’’). With a dominant elastic behaviour, the PSIM is able to constitute a 
barrier in the intestines that protects the underlying epithelial surfaces from mechanical stress 
and hydrates the epithelial cells (Atuma et al., 2001)  (Bansil and Turner, 2006). 
  
3.3.2.2	  Strain	  Sweeps	  
 
Several replicates of strain sweeps with strain range of 1*10-5-10 were run on different PSIM 
samples. Overall the trends are similar, with small shifts in the values of the moduli and phase 
angles. The most representative strain sweeps is presented in Figure 3.25.  
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Figure 3.25 Strain sweep of PSIM with increasing strain in the range 1*10-5-10. Run at a frequency of 
1 hertz and a temperature of 25 °C.  
The increasing strain sweep of PSIM presented in Figure 3.25 indicates a smooth transition 
from an elastic-like behaviour of the mucus at lower strains, to a more viscous-like behaviour 
when the imposed strains reach 0.8 and increase. Data points at strains 0.00001-0.0007 were 
omitted because of noise in the data. There is a clear viscoelastic region at strains 0.0007 – 
0.05, where the storage modulus values (G’), loss modulus values (G’’) and hence the phase 
angle values are kept at the same level, and are independent of the strain (Zhong and Daubert, 
2013). The loss modulus (G’’) values exceed the values of the storage modulus (G’) at strain 
0.8, when the phase angle reaches 45 degrees. The stress curve shows how much stress is 
needed to induce the strain. The stress increases broadly linearly with increased strain. As the 
mucus becomes less able to resist deformation, the gradient of the stress curve changes, and 
less stress is needed to induce the same strain (Taylor et al., 2005a).  
 
The gradual weakening of the gel, indicated by the rheological parameters, might on the 
molecular level in part be attributed to the “dangling chain ends” of the mucins (Taylor et al., 
2003). As the imposed strain increase some bonds are broken, and some bonds are formed. 
The weakening of the gel occurs when the rate at which the bonds break are higher than the 
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rate at which new bonds form (Bøgh et al., 2013). When the strain is removed, the broken 
bonds of the gel reform (Taylor et al., 2003). Rheological reversibility is important for PSIM 
as it enables the mucus to be reused, as discussed below. 
 
To illustrate the variation in the strain sweep results between the PSIM samples, the two 
samples yielding the highest and lowest values of the rheological variables are presented in 
Figure 3.26.  
 
Figure 3.26 Strain sweeps of PSIM of two different samples, sample 1 represented by circles and 
sample 2 represented by triangles. The sweeps were run in the strain range 1*10-5-10, a frequency of 1 
Hertz and a temperature of 25 °C.  
 
The plots in Figure 3.26 reflect the differences in the general trends of the strain sweeps of 
PSIM, which are relatively small. The largest variations are found in the absolute values of 
the storage (G’) and loss moduli (G’’), but the near identical phase angles and the identical 
slopes of the stress curves confirm a similar behaviour in the PSIM samples when they are 
exposed to increasing strains. Similar phase angles implies that the relationship between the 
storage modulus (G’) and loss modulus (G’’) from one sample to the next is the same (Picout 
and Ross-Murphy, 2003). 
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3.3.2.3	  Investigation	  of	  thixotropic	  effects	  of	  PSIM	  
 
The thixotropic effects of PSIM were investigated by running two up-down strain sweeps on 
two different samples in the strain range 1*10-5-10. Thixotropic effects would be reflected in 
an up-down strain sweep when the rheological variables do not follow the same path at 
increasing and decreasing strains. The two up-down strain sweeps run yielded similar results. 
One of them is presented in Figure 3.27. 
 
Figure 3.27 Up-down strain sweep of PSIM, where the circles represent values at increasing strains 
and the triangles represent values at decreasing strains. The sweep was run at a frequency of 1 Hertz 
and at 25 °C.  
The up-down strain sweep in Figure 3.27 shows that the rheological variables do not follow 
the same path with increasing and decreasing strains. Data at strains 0.0001-0.001 was 
omitted because of noise. The moduli values are similar in the strain range ~1-10, where the 
PSIM show a viscous-like behaviour. Within this region the mucus has a completely shear 
thinning behaviour (Lai et al., 2009b). As the strains starts to decrease from 10 and reach the 
point where the transition from a viscous-like behaviour to a more elastic-like behaviour 
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occurs, the path of the rheological variables starts to deviate from the path seen as the strains 
increased. This occurs because the bonds and interactions in the matrix are not able to rebuild 
themselves in the given time scale of the experiment. The rheological reversibility of the 
mucus is in this region not only dependent on the imposed strain, but also on time (Moller et 
al., 2006).  
 
Rheological reversibility includes both shear thinning, which is dependent on strain/shear, and 
thixotropy, which is dependent on strain/shear and time (Picout and Ross-Murphy, 2003) 
(Moller et al., 2006). The gradual weakening of the PSIM in Figure 3.25 & Figure 3.26 
indicated shear thinning properties of the PSIM, and both shear thinning and thixotropic 
behaviour were observed in the up-down strain sweep of Figure 3.27, as discussed above.  
 
As already mentioned, rheological reversibility is an expected and crucial property of PSIM 
as it enables the reuse of mucus (Taylor et al., 2005a). Of the 10 litres of mucus that are 
secreted in the human GI tract every day, 9.8 litres of it is reused (Cone, 2009). If the mucus 
did not have the ability to rebuild disrupted bonds, interactions and entanglements, the mucus 
gel would maintain its’ liquid properties after strain/shear induced flow, and could not be 
reused. A loss of the mucus’ viscoelastic properties would have rendered it non-functional as 
a lubricant or assisting in locomotion (Taylor et al., 2005a), and it would have been 
eliminated with the faeces, making the body spend great amounts of energy continuously 
generating new mucus (Cone, 2009). 
 
The results from the rheological measurements of PSIM shows that there are some variations 
between replicate experiments on different PSIM samples, especially in the absolute values of 
the storage moduli. However, the phase angle of these replicate experiments is quite similar, 
reflecting the same behaviour of the PSIM samples. The variation observed are most likely 
due to natural variation, which is expected between mucus extracted from different places in 
the intestine or between different individuals (Girod et al., 1992).  
 
 
3.3.3	  Rheological	  measurements	  of	  biosimilar	  mucus	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Frequency sweeps and strain sweeps were performed on biosimilar mucus samples for 
verification of viscoelastic behaviour and properties, and comparison with the PSIM.  
 
3.3.3.1	  Frequency	  sweeps	  
 
Three replicate frequency sweeps were run on different biosimilar mucus samples from the 
same batch, in the frequency range 0.01-10 Hertz and with a fixed strain within the linear 
viscoelastic region. The linear viscoelastic region was found prior to the frequency sweeps by 
running strain sweeps in the strain range 1*10-5-10 on different biosimilar mucus samples. A 
frequency sweep was also run on a fourth biosimilar mucus sample, from a second biosimilar 
mucus batch. On several samples of biosimilar mucus from the second batch stress controlled 
frequency sweeps were run in the frequency range 0.1-10 Hertz. The four replicates of the 
strain controlled frequency sweeps are plotted together in Figure 3.28. 
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Figure 3.28 Four replicate strain controlled frequency sweeps of different biosimilar mucus samples, 
in the frequency range 0.001-10 Hertz. The fixed strain for all the measurements was within the linear 
viscoelastic region, and the temperature was 25 °C. The moduli values are presented in the upper plot, 
and the phase angle values are presented in the lower plot.  
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The four replicate frequency sweeps presented in Figure 3.28 shows that biosimilar mucus has 
an elastic-like dominant behaviour at strains 0.001-7 Hertz. The loss moduli values of the 
biosimilar mucus have a steep unexpected increase at frequencies 0.1-10 Hertz, which renders 
the behaviour of the biosimilar mucus more viscous-like in this frequency range. This is also 
reflected in the phase angles, which increase at the highest strains and reach well beyond 45 
degrees. These trends are observed in three out of four samples. Similar to the PSIM 
discussed above, the biosimilar mucus was expected to show a dominant elastic behaviour 
through the whole frequency sweep, as the increased frequency is expected to inhibit 
rearrangement of the bonds and interactions in the gel matrix of the biosimilar mucus, so that 
an increased elastic-like behaviour is seen through the whole frequency range.  
 
The unexpected behaviour at the highest frequencies, where the loss modulus (G’’) values are 
higher than the storage modulus values (G’), implies that the bonds and interactions of the 
mucus have time to rearrange in this high frequency range. This is contradictory to theory 
(Zhong and Daubert, 2013), but might be explained by an occurrence of phase transition of 
the mucin molecules of the biosimilar mucus. Sigma mucin type III, which are partially 
purified mucins from pig stomachs, have previously been proven to enter a fluid liquid 
crystalline phase at temperatures above 24.8 °C, but only at concentrations 24-28 % (w/w) 
(Davies and Viney, 1998). However, this does not exclude the possibility of a phase transition 
in the Sigma mucin type II molecules of the biosimilar mucus. For the Sigma mucin type III 
in the studies of Davies and Viney, the interdigitation of the sugar side chains of the mucin 
molecules was though to be responsible for the phase transition (Davies and Viney, 1998). It 
is not unreasonable to think that this might have occurred in the Sigma mucins type II of the 
biosimilar mucus as well. The dense sugar side chains of the mucin molecules are the areas 
best protected from protease cleavage by the non-mucin proteins that are not purified from the 
mucins. The sugar side chains have probably kept most of the original structure found in the 
pig stomach in both Sigma mucin type II and type III.  
 
The cause of the unexpected behaviour observed, might also be differences in the gel network 
in the biosimilar mucus, compared to the gel network of native mucus, like PSIM. The gel 
network of the biosimilar mucus comprise of Sigma mucin type II, supported by the 
scaffolding properties of PAA. This gel network is not built the in the same manner as the gel 
network of native mucus, which is mainly held by mucins alone (Lai et al., 2009b), and might 
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therefore also behave differently. Nevertheless, the biosimilar mucus was developed for cell 
compatibility with Caco-2 cells for drug absorption studies, and it is not likely that 
experiments as such introduce conditions corresponding to frequencies 7-10 Hertz. 
 
Even though small batch variations can be observed in the frequency sweeps, all the samples 
follow the same trends in the frequency range 0.001- 2 Hertz. Above this frequency there are 
some differences in the moduli values, but in three out of four samples the values of the 
storage modulus hits a peak value and then decreases at the highest frequencies.  In three out 
of the four samples the loss modulus keeps increasing until the frequency reach 10 Hertz. 
These results might indicate that the rheological behaviour of the biosimilar mucus is most 
stable at frequencies below 2 Hertz. 
 
In the linear viscoelastic region the stress and strain is independent of the frequency (Picout 
and Ross-Murphy, 2003). To make sure that the stress did not increase when the strain was 
fixed and thereby could have had an effect reflected in the high loss modulus (G’’), the results 
from a stress controlled frequency sweep were compared to two of the results from the strain 
controlled frequency sweeps, presented in Figure 3.29. The results from the stress controlled 
frequency sweeps were close to identical (not included). 
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Figure 3.29 Frequency sweeps of biosimilar mucus with increasing frequencies, where two of the 
samples are strain controlled and one of the samples are stress controlled. The stress/strain were kept 
within the linear viscoelastic region, and all the measurements run at 25 °C.  
As seen in Figure 3.29 the curves of the moduli and phase angle of the stress controlled 
frequency sweep of sample 5 follow almost the exact same curves as the corresponding 
variables of the strain controlled frequency sweep of sample 4. This indicates that the high 
values of the loss moduli in the frequency range of 0.1-10 Hertz is not an effect of increasing 
stress during the strain controlled frequency sweeps, since the exact same behaviour is 
observed in a stress controlled frequency sweep and a strain controlled frequency sweep. 
Sample 4 and sample 5 were from the second mucus batch, while sample 1 was from the first 
mucus batch. This again demonstrates some batch variations for the biosimilar mucus. 
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3.3.3.2	  Strain	  Sweeps	  
 
Several strain sweeps in the strain region 1*10-5- 10 were run on different biosimilar mucus 
samples, both from batch number one and batch number two. In general, the trends in the 
strain sweeps are similar, with some variation in the absolute values of the moduli. The most 
representative strain sweep is presented in Figure 3.30. 
 
 
 
Figure 3.30 Strain sweep of biosimilar mucus with increasing strains, run at a fixed frequency of 1 
Hertz and a temperature of 25 °C.  
 
The increasing strain sweep of biosimilar mucus presented in Figure 3.30 shows that no 
catastrophic failure occurs. Data points at strains 0.00001 – 0.004 have been omitted because 
of noise. A smooth transition from an elastic-like behaviour at low strains, to a viscous-like 
behaviour at high strains is observed. The behavioural transition occurs at strain 0.4, when the 
phase angle reaches 45 degrees. Just like the PSIM, the interactions and bonds of the gel 
network in the biosimilar mucus starts to break at a faster rate than new interactions are 
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formed as the imposed strain is increased (Bøgh et al., 2013), and a weakening of the gel 
occurs. The majority of the behavioural change is due to the decrease of the elastic-like 
behaviour rather than a big change in the viscous-like behaviour, seen as a steep decrease of 
the graph of the storage modulus (G’) compared to a minor decrease of the graph of the loss 
modulus (G’’) with increasing strains. The stress curve gradually levels off in the entire strain 
range, and indicates that less and less stress is needed to induce the strain, which fits well with 
a gradual weakening of the gel. 
 
The same trends are observed in all the strain sweeps of biosimilar mucus, with some 
variation in the absolute values of the moduli. The sweeps of highest and lowest rheological 
variables are presented in Figure 3.31 to illustrate the variation between the mucus samples. 
 
  
Figure 3.31 Strain sweeps of increasing strains run on two different biosimilar mucus samples taken 
from mucus batch number one. Circles represent sample 1 and triangles represent sample 6. The fixed 
frequency of the sweeps were 1 Hertz, and the temperature 25 °C.  
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The two strain sweeps of Figure 3.31 illustrates the variation in the rheological variables 
between the biosimilar mucus samples. Even thought it might seem like a substantial variation 
in the absolute values of the moduli and the stress curves, the phase angles of the two 
measurements are almost identical, which indicates the same rheological behaviour of the 
samples (Picout and Ross-Murphy, 2003). (For sample 1 data points in the strain region 
0.00001 – 0.0001 are omitted because of noise, and for sample 6 data points in the strain 
region 0.00001- 0.002 are omitted because of noise.) No specific batch variation was 
observed between the samples of batch one and batch two. The shear thinning properties of  
biosimilar mucus is desired, as shear thinning properties was also observed in the PSIM. The 
biosimilar mucus should mimic the rheological properties of PSIM as close as possible, for it 
to be as good an intestinal mucus model system as it can be, in rheological terms. 
 
3.3.3.3	  Investigation	  of	  the	  thixotropic	  effects	  of	  biosimilar	  mucus	  
 
The thixotropic effects of the biosimilar mucus were investigated by running two up-down 
strain sweeps in the strain range 1*10-5-10. Time dependent thixotropic effects are verified if 
the plots of the rheological variables do not follow the same path when the strain is increasing 
and when the strain is decreasing. The two up-down sweeps yielded very similar results. One 
of the sweeps is plotted in Figure 3.32. 
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Figure 3.32 Up-down strain sweep of biosimilar mucus, in the range 1*10-5-10. The circles represent 
the moduli and phase angle values with increasing strains, and the triangles represent the moduli and 
phase angle with decreasing strains. The fixed frequency of the strain sweep was 1 Hertz, and the 
temperature 25 °C.  
As shown in Figure 3.32, the rheological variables do not follow the same path with 
increasing and decreasing strains in the strain range 0.001-08. (Strain values in the range 
0.00001-0.0002 are omitted because of noise in the data). The variables follow the same path 
at strains higher than 0.8, and behaves in a completely shear thinning manner, being viscous-
like. At the point where the behavioural transition occurs (phase angle of 45 degrees) the 
paths of the rheological variables of increasing and decreasing strains starts to deviate. This 
occurs because the interactions broken as the strain increased are not able to rebuild 
themselves in the given time scale of the measurement when the strain decrease. Just like the 
PSIM, the biosimilar mucus holds thixotropic properties, which are dependent on the strain 
and the time frame of the experiment (Moller et al., 2006).  
 
The rheological reversibility by shear thinning and thixotropy observed in the strain sweeps of 
biosimilar mucus are positive results for the applicability of the biosimilar mucus as a 
intestinal mucus model system, since native intestinal mucus is dependent on these properties, 
which enable reuse of the mucus in the intestines (Taylor et al., 2003).  
 
 89 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
Batch variations were observed only in the frequency sweeps, while strain sweep 
measurements did not produce these differences. This might indicate that there were some 
variation between the batches that affected the time frame of the rearrangement of the 
different bonds and interactions of the biosimilar mucus gel, while it did not affect the shear 
thinning properties of the gel. 
 
When comparing the rheological measurements of the biosimilar mucus of this master thesis 
to the results of Bøgh et al (Bøgh et al., 2013) (data not shown), the results are broadly 
similar, revealing the same trends. Obtaining desired rheological behaviour from the 
biosimilar mucus was expected, because the biosimilar mucus has been optimized to mimic 
the rheological properties of PSIM.   
 
3.3.4	   Comparison	   of	   rheological	   measurements	   of	   PSIM	   and	  
biosimilar	  mucus	  
 
The rheological measurements have revealed that the biosimilar mucus holds desirable 
rheological properties, similar to the properties observed in PSIM. The rheological profiles of 
the two mucous systems were directly compared to increase the understanding of the 
similarities and differences of the rheological profiles, and enable a more accurate evaluation 
of the applicability of the biosimilar mucus as a small intestinal mucus model system.  
 
3.3.4.1	  Frequency	  sweeps	  
 
Results from frequency sweeps of sample 1 of the PSIM and sample 1 from batch one of the 
biosimilar mucus were chosen to illustrate the results of the frequency sweeps of each mucous 
systems, as these were the most representative results from each mucous system. The moduli 
values are plotted together in the upper plot, and the phase angles are plotted in the lower plot 
in Figure 3.33. 
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Figure 3.33 Frequency sweeps in the frequency range 0.001-10 Hertz of PSIM (black graphs) and 
biosimilar mucus (white graphs). The strain was fixed within the linear viscoelastic region. The 
temperature of both the measurements was 25 °C. The moduli values are presented in the upper plot, 
and the phase angle values are presented in the lower plot. 
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Upon comparison of the frequency sweeps of the PSIM and biosimilar mucus in Figure 3.33 it 
is evident that there are some dissimilarities in the behaviour of the two systems when 
exposed to increasing frequencies.  
 
The most obvious difference is the absolute values of the storage moduli (G’). The PSIM has 
storage modulus (G’) values up to ten times higher than the corresponding values found in the 
biosimilar mucus measurements. The slope of the storage modulus (G’) of the PSIM is also 
much steeper than the slope of the storage modulus (G’) of the biosimilar mucus. The 
absolute values of the loss moduli (G’’) are more similar, and the slopes only deviate from 
each other in the frequency range 5-10 Hz, where the two graphs eventually intersect. The 
increase of the loss modulus (G’’) of the biosimilar mucus, is due to the unexpected behaviour 
discussed earlier. 
 
The phase angle is the more descriptive variable for the behaviour of the two systems (Picout 
and Ross-Murphy, 2003) (Taylor et al., 2004) (Taylor et al., 2005b). Broadly speaking the 
phase angles follow the same trends in the frequency range 0.001- 0.03 Hertz, with a low 
phase angle reflecting the dominant elastic-like behaviour of both the mucous systems. At 
frequencies >0.03, the phase angles of the PSIM and biosimilar mucus are dissimilar, which 
are mainly due to the unexpected behaviour of the biosimilar mucus at high frequencies. 
 
3.3.4.2	  Strain	  Sweeps	  
 
The most representative strain sweeps of each mucous system were plotted together in Figure 
3.34 for comparison. The conditions of both sweeps were similar, with a fixed frequency of 1 
Hertz and a temperature of 25 °C.  
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Figure 3.34 Strain sweeps with increasing strains, of PSIM (black graphs) and biosimilar mucus 
(white graphs). The fixed frequency of the measurements was 1 Hertz and the temperature set to 25 
°C. The moduli values are presented in the upper plot, and the phase angle and stress values are 
presented in the bottom plot. 
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Data points in the strain region 0.00001-0.0004 of the PSIM measurements and the data 
points in the strain region 0.00001-0.002 of the biosimilar mucus are omitted because of 
noise.  
 
As seen in Figure 3.34, the same trends are observed in the storage moduli (G’) of PSIM and 
biosimilar mucus, with a smooth transition in behaviour from elastic-like to viscous-like, and 
with no signs of catastrophic failure. The loss moduli (G’’) trends deviate somewhat more 
from each other in the two mucous systems. Nevertheless, the phase angles of the two 
systems are broadly similar, which implies a quite similar behaviour in the PSIM and 
biosimilar mucus when exposed to increasing strains. The behavioural transition occurs at 
nearly the same strain. The stability of the PSIM is seemingly somewhat higher than the 
stability of the biosimilar mucus, since the phase angle of the bioismilar mucus increases at 
lower strains and in a steeper manner, than the phase angle of the PSIM. This is not surprising 
as the gel matrix of the PSIM, which is mainly build up of mucins, is expected to be stronger 
and more stable than the gel matrix in biosimilar mucus, which consists of Sigma mucins 
supported by PAA. The stress curves of the two systems follow almost the same slopes, but 
deviates from each other in the strain range 5-10. There are differences in the absolute values 
of all the rheological variables presented, and with the exception of the phase angle all the 
variables are higher in the PSIM measurements.  
 
The differences in the rheological profiles of PSIM and biosimilar mucus observed in the 
frequency sweeps and the strain sweeps, are probably due to the differences found in the 
structure of the gel network and components of the two systems. As the mucins found in the 
stomach and the mucins found in the small intestines are structurally related (Sellers et al., 
1991) (Celli et al., 2005), one might expect that Sigma mucins, originating from the stomach 
of pigs, and PSIM should hold properties that are quite similar. The gastric mucus is in 
general somewhat more rigid than the small intestinal mucus (Mantle and Allen, 1981), and 
therefore one might expect the biosimilar mucus to comprise a more rigid gel than PSIM, and 
that differences in the rheological measurements reflects this. However, it is the opposite that 
is seen in the rheological measurements, and also observed in the distribution studies (section 
3.1). 
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The reason for this is likely that the Sigma mucins of the biosimilar mucus do not have the 
same structure as when they were in the pig stomach. The isolation and purification process 
has most likely altered the physical and chemical properties of the Sigma mucin to the extent 
were reconstruction of the exact structure found in the pigs’ stomach is not possible. This is 
supported by a study by Kočevar-Nared and colleagues (Kočevar-Nared et al., 1997). The 
Sigma mucin type II is a crude mixture of mucins, and the sugar and amino acid composition 
has not been determined (Sigma-Aldrich, 2011). The mucins found in mucus like PSIM are 
large molecules with molecular weights ranging from 10-40 MDa, linked together by mucin 
monomers of 0.3-0.5 MDa (Lai et al., 2009a). The result of the isolation and purification 
process of the Sigma mucins is likely fragmentation of the mucins, to a lower molecular 
weight than what is found in the PSIM. The purification process in it itself should not 
fragment the mucins, but it might occur if some of the non-mucin components in the Sigma 
mucin product are proteases naturally found in the mucus. Because of this, the Sigma mucins 
do not form a gel network when mixed into the HEPES buffer. They need the scaffolding 
properties of the PAA to form a proper gel network. The viscoelastic properties of biosimilar 
mucus is hence mainly a function of both the Sigma mucins and the PAA, but might be 
dependent on the lipids and bovine serum albumin as well (Bøgh et al., 2013), whereas the 
viscoelastic properties of the PSIM is predominantly a function of the mucin matrix (Lai et 
al., 2009b). Despite that the bisoimilar mucus is optimized to mimic the rheological profile of 
PSIM, it will be nearly impossible to get the exact same rheological profiles from the two 
systems when the components and the structure of the two systems deviate to this extent. 
 
3.3.5	  Control	  rheological	  measurements	  of	  Sigma	  mucin	  solutions	  
 
Control rheological measurements of Sigma mucin in 10 mM HEPES buffer containing 1 mM 
MgSO4 and 1.3 mM CaCl2 were run in order to verify the necessity of the non-Sigma mucin 
components of the biosimilar mucus. Solutions of three different concentrations were made;  
5 % (w/v) – which is the same mucin concentration as the biosimilar mucus, 8 % (w/v) and 10 
% (w/v). Different concentrations of the solutions enabled to check for concentration 
dependent behaviour.  
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The experimental set up differed somewhat from the set up of the biosimilar mucus and 
PSIM, as no proper rheological results were expected, since the solutions had a sol-like 
consistency.  For each of the three Sigma mucin solutions six succeeding measurements were 
performed; strain sweep and frequency sweep at 15 °C, strain sweep and frequency sweep at 
25 °C and strain sweep and frequency sweep at 37 °C. Different temperatures enabled to 
check for temperature dependent behaviour. 
 
3.3.5.1	  Strain	  sweeps	  
 
Strain sweeps in the strain range 1*10 -5-100 with a fixed frequency of 1 Hertz, were run on 
15 °C, 25 °C and 37 °C for each of the three Sigma mucin solutions. After each strain sweep a 
frequency sweep were run on the same temperature. 
 
Some general trends could be seen in all the strain sweeps, presented in Appendix D. Three of 
the strain sweeps, one for each solution concentration at 15 °C, are presented in Figure 3.35. 
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Figure 3.35 Strain sweeps of solutions of Sigma mucin dissolved in a 10 mM HEPES buffer 
containing 1.3 mM CaCl2 and 1 mM MgSO4. All the sweeps were run at a frequency of 1 Hertz. The 
upper plot is a sweep of the 5 % (w/v) solution, run at a temperature of 15 °C. The middle plot is a 
sweep of the 8 % (w/v) solution, run at a temperature of 15 °C. The bottom plot is a sweep of the 10 % 
(w/v) solution, run at a temperature of 15 °C. 
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In all the strain sweeps the values of the storage moduli (G’) and the loss moduli (G’’) are 
very low. This reflects the inability of the Sigma mucin to form a gel when dissolved in the 
buffer, and hence the absence of a characteristic viscoelastic behaviour, which were as 
expected. As discussed above, the inability to form a gel network is probably due to the low 
molecular weight of the Sigma mucins, which has been fragmented due to photolytic action of 
non-mucin proteins found in the Sigma mucin product. 
 
Some general trends are observed in all the strain sweeps. The absolute values of the storage 
moduli (G’) show no viscoelastic region at the lowest strains as it instantly starts to decrease 
when the strain increase, and hits a minimum when the strain is 1. At higher strains the 
absolute values starts to increase. This kind of behaviour is not expected as this implies that 
the behaviour becomes more elastic-like at the highest strains, but can be explained by that 
mucins can create interactions in shear (Corfield, 2000). New ordered structures might form 
by the glycosylated side chains of mucin, which is presumed to have been relatively well 
preserved, due to the inaccessibility of proteases naturally found in the Sigma mucin II.  
 
The absolute values of the loss modulus (G’’) decrease to some degree in the entire strain 
range. The phase angle of all the strain sweeps reaches a peak of 90 degrees at strains 1. The 
stress curves of the strain sweeps are quite linear, but some of them tend to level off at the 
highest strains, indicating that less stress needed to induce the strains in this region.  
 
Except for the trend of the increasing storage modulus values at strains ~1 that diminishes 
with increasing Sigma mucin concentration, no distinctive temperature or concentration 
effects are seen in the strain sweeps of the Sigma mucin solutions.  
 
3.3.5.2	  Frequency	  Sweeps	  
 
Frequency sweeps of the three Sigma mucin soluitons were run, each at 15 °C, 25 °C and 37 
°C. Three of the plots, one for each concentration at a temperature of 37 °C, is presented in 
Figure 3.36. 
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Figure 3.36 Frequency sweeps in the frequency range 0.001-10 Hertz of Sigma mucin dissolved in 10 
mM HEPES buffer-solutions containing 1.3 mM CaCl2 and 1 mM MgSO4. The chosen fixed strain 
were 0.05. The upper plot represents a 5 % (w/v) solution, the middle represents a 8 % (w/v) solution, 
and the lower represent a 10 % (w/v) solution. All measurements were run at 37 °C. 
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In all the frequency sweeps some general trends are observed, independent of the Sigma 
mucin concentration or the temperature of the measurement. The absolute moduli values are 
very low, and both storage moduli (G’) and loss moduli (G’’) increase in the entire frequency 
range. The exception is when the storage moduli (G’) hits a sudden minimum at ~5 Hertz. 
This is reflected in the phase angle which peaks at ~5 Hertz. According to theory the patterns 
of the storage modulus (G’) and the loss modulus (G’’) is consistent with a concentrated 
solution (Zhong and Daubert, 2013), which fits well here. 
 
A U-shape is observed in the graphs of the phase angle, which is most dominant in the 
frequency sweeps of 15 °C and diminish at higher temperatures. This might be a temperature 
dependent effect, but can also be an effect of the experimental set-up, where the solutions 
exposed to the measurements of the highest temperatures previously have been exposed to the 
measurements of lower temperatures, which may have further weakened the system for the 
latter measurements.  
 
The rheological measurements on the Sigma mucin solutions yielded results as expected, 
consistent with poor viscoelastic properties. Changing the temperature of the measurements or 
doubling of the concentration of Sigma mucin from 5 % (w/v), which is the concentration of 
the biosimilar mucus, to 10 % (w/v) had no effect. This has also been reported earlier 
(Kočevar-Nared et al., 1997). 
 
The critical overlap concentration of the Sigma mucins is proportional to the molecular weigh 
of the molecules (Clasen et al., 2006). The Sigma mucins probably have such a low molecular 
weight that it does not support the formation of the mucin matrix found in native mucus. For 
creation of a gel like structure when utilizing Sigma mucins, the non-mucin components of 
the biosimilar mucus are necessary, in particular the PAA that contributes with scaffolding 
properties. 
 
 
 
 
 100 
	  
3.	  Results	  &	  Discussion	  
	  
	   	  
3.3.6	  Conclusive	  remarks	  on	  the	  rheological	  measurements	  of	  PSIM,	  
biosimilar	  mucus	  and	  Sigma	  mucin	  solutions	  
 
The results from the frequency sweeps and strain sweeps of PSIM showed that the PSIM has 
behaviour as expected for the maintenance of the protective barrier in the intestines and reuse 
of the mucus, with dominant elastic behaviour with increasing frequencies, and rheological 
reversibility, both shear thinning and thixotropic. 
 
In general the biosimilar mucus show rheological behaviour as desired from an intestinal 
mucous model system. The frequency sweeps revealed a frequency dependent dominant 
elastic behaviour, but deviated from what was expected in the frequency range 7-10 Hertz, 
where the behaviour changed to more viscous-like. The strain sweeps showed a smooth 
transition from an elastic-like behaviour to a viscous-like behaviour and hence shear thinning 
properties. In addition time dependent thixotropic properties were verified by up-down strain 
sweeps. 
 
Based on the comparison of the rheological profiles of PSIM and biosimilar mucus, an 
evaluation about the biosimilar mucus as an applicable small intestinal mucous model system 
can be done. The results of the rheological profile showed that overall the PSIM has 
somewhat higher mechanical properties than the biosimilar mucus, but that the behaviour is 
broadly similar if the strain and frequency are kept low. The biosimilar mucus was originally 
developed for compatibility with the Caco-2 cells, which are mainly utilized in intestinal drug 
absorption studies, since native mucus is not compatible with the cell line as it disrupts the 
cell monolayer (Boegh et.al, 2013). In nanoparticle drug delivery studies is not likely to apply 
very high frequencies or strains to the mucus, and in rheological terms the biosimilar mucus 
might be an applicable intestinal mucous model system.  
 
Sigma mucin in HEPES buffer do not comprise a model system with rheological properties 
mimicking that of intestinal mucus, which emphasize the necessity of the non-mucin 
ingredients of the biosimilar mucus. 
 101 
	  
4.	  Future	  work	  
	  
	   	  
4. Future work 
4.1	  Distribution	  studies	  
 
It would have been interesting, if possible, to replicate the experiments were the distribution 
of nanoparticles were applied on top of mucus were investigated, but with Caco-2 cells 
coating the bottom of the glass chambers. By coating the wells with Caco-2 cells, it is likely 
that the mucus would have been more stable due to interactions with the glycocalyx (Lochner 
et.al, 2003). In this way perturbations might not have had such an impact on the distribution 
of the nanoparticles. Also, it might have been possible to add a thinner layer of mucus on top 
of the cells, which would make it easier for the laser of the confocal microscope to find and 
visualize the nanoparticles (assuming that the Caco-2 cells are readily penetrated by the laser). 
 
4.2	  The	  plate	  method	  
In the plate method it was discovered that the fluorescence intensity detected was wavelength 
dependent. It could have been interesting to investigate the background fluorescence intensity 
of PSIM and bisoimilar mucus on different wavelengths. If there had been found a 
wavelength area in the light spectra where the PSIM and biosimilar mucus did not yield any 
background fluorescence, it would have been interesting to further develop the method. This, 
however, requires the existence of fluorescent nanoparticles on the market with ex./em. 
maxima within the given wavelength area. 
 
4.3	  Further	  evaluation	  of	  the	  biosimilar	  mucus	  
 
An evaluation has been done on the applicability of the biosimilar mucus as a model system 
for small intestinal mucus in nanoparticle drug delivery/absorption studies. However, more 
studies should be made for a more thorough and complete evaluation. E.g. particle mobility in 
the biosimilar mucus could be tested by multiple particle tracking (MPT) or fluorescence 
recovery after photo bleaching (FRAP), and compared to similar measurements of PSIM.
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5. Conclusion 
 
The development of the plate method looked promising up until it was discovered that high 
background fluorescence was detected in PSIM and biosimilar mucus, which might be due to 
Raman scattering. The further development of the plate method was terminated.  
 
The results form the distribution studies and comparison of the rheological profiles of PSIM 
and biosimilar mucus, suggest that the biosimilar mucus is an applicable intestinal mucus 
model system for studies of nanoparticle absorption through mucus and into cells. The 
distribution studies showed that different nanoparticles distribute in biosimilar mucus and 
PSIM in a comparable manner, and that the biosimilar mucus did not significantly aggregate 
or alter the nanoparticles, which could prevent the epithelial cells from nanoparticle uptake. It 
was also shown that the distribution pattern of nanoparticles in the two mucous model 
systems could not be predetermined based on the charge and/or size of the nanoparticle. 
Neither the biosimilar mucus or the PSIM were robust enough for the experimental conditions 
of studying the nanoparticle distribution and adsorption of nanoparticles on top of the mucus, 
and were also too dense for the laser of the confocal microscope to penetrate properly. The 
biosimilar mucus was shown to have broadly the similar viscoelastic properties as PSIM, as 
long as the strain and frequency were kept low. 
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Appendix A - Additional info to section 2 Materials & Methods 
 
A.1 Purification protocol of the pig gastric mucins 
 
The purification protocol of pig gastric mucins was provided by Professor J.P. Pearson at the 
Institute for Cell and Molecular Biosciences, University of Newcastle upon Tyne. 
 
 Preparation of purified mucin samples 
Pig gastric mucus gels were removed from the mucosa and immediately transferred into an 
ice cold cocktail of protease inhibitors in phosphate buffer (mucus to buffer ratio 1:4 v/v), pH 
6.5, to prevent degradation by endogenous proteases.  Mucus gel was solubilised in the 
inhibitor cocktail by high speed homogenisation in a Waring Blender for 1 minute.  Soluble 
material was separated from insoluble cell debris by centrifugation (8000g, 1 hour, 4oC).  The 
resulting supernatant was further purified to remove protein and nucleic acid by equilibrium 
density gradient ultracentrifugation in caesium chloride (CsCl) (Starkey et al., 1974).  CsCl 
was added to give a starting density of 1.42 g/ml, and the solution centrifuged at 100,000g for 
48 h at 4oC, using a fixed angle rotor. 
 
The contents of each tube were removed as nine equal fractions with care being taken not to 
disturb the density gradient.  The density of each fraction was measured, followed by 
exhaustive dialysis against distilled water at 4oC.  Dialysed fractions were assayed for 
glycoprotein, protein and nucleic acid.  Fractions rich in protein and nucleic acid were 
discarded, and those rich in glycoprotein were pooled, freeze dried and stored at –20oC. 
 
Table A.1 Concentration and action of protease inhibitors within the proteolytic inhibitor 
cocktail 
Protease inhibitor Concentration 
(mM) 
Mode of action  
 
Phenylmethylsulphonyl 
fluoride 
(PMSF) 
3 Inhibitor of serine proteases, e.g., elastase 
hydrolyses peptide bond at C-terminal side, 
and cathepsin and trypsin removes N-
terminal dipeptides. 
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Sodium iodoacetate 1 Inhibitor of thiol-dependent proteases, e.g., 
cathepsin B and other disulphide dependent 
enzymes. 
Benzamidine 
Hydrochloride 
15 Specific inhibitor of trypsin and trypsin-
like serine proteases (hydrolysis of 
proteins, peptides and amino acids). 
Na2 EDTA 10 Inhibitor of metallo-dependent proteases, 
e.g., Ca2+ dependent enzymes. 
N-ethylmaleimide 10 Prevents disulphide group exchange. 
a-amino caproic acid 100 Inhibitor of plasminogen activation to 
serine protease plasmin (hydrolyses peptide 
and ester bonds). 
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A.2 List of chemicals utilized in the thesis 
 
Table A.2 A list of the chemicals utilized in the practical work of the master thesis. 
Chemical Producer Lot number 
Linoleic acid Sigma Aldrich Co., St.Louis, 
USA 
SLBB2791V 
Cholesterol Sigma Aldrich Co., St.Louis, 
USA 
SLBC7554V 
L-α-phosphatidylcholine Sigma Aldrich Co., St.Louis, 
USA 
BCBK8990V 
Polysorbate 80 Sigma Aldrich Co., St.Louis, 
USA 
BCBH5882V 
Sigma porcine gastric mucin type II: 
crude 
Sigma Chemical Co., St.Louis, 
USA 
26H1004 
Carbopol 934P /PAA Reckitt & Colman Products, 
Kingston Upon Hull, UK 
DS9068 
Bovine Serum Albumin Sigma Chemical Co., St.Louis, 
USA 
108H0914 
HEPES Sigma Aldrich Co., St.Louis, 
USA 
040M5432V 
NaCl Merck KGaA (Darmstadt, 
Germany 
K42150704 116 
CaCl2 Merck KGaA (Darmstadt, 
Germany 
K43533936 241 
MgSO4 Merck KGaA (Darmstadt, 
Germany 
0076819 
Dow Corning ® 200/100S fluid VNR International LTD 
(Butterworth, UK 
  ? 
FluoSpheres® carboxylate modified 
microspheres, 0.2 µm, yellow-green 
fluorescent (505/515), 2 % solids 
Invitrogen Ldt., Paisley, UK 714135 
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FluoSpheres® amine modified 
microspheres, 0.2 µm, yellow-green 
fluorescent (505/515), 2 % solids 
Invitrogen Ldt., Paisley, UK          513683 
FluoSpheres® carboxylate modified 
microspheres, 0.1 µm, yellow-green 
fluorescent (505/515), 2 % solids 
Invitrogen Ldt., Paisley, UK 1173467 
FluoSpheres® carboxylate modified 
microspheres, 0.1 µm, red 
fluorescent (580/605), 2 % solids 
Invitrogen Ldt., Paisley, UK           483011 
FluoSpheres® carboxylate modified 
microspheres, 0.2 µm, red 
fluorescent (580/605), 2 % solids 
Invitrogen Ldt., Paisley, UK           646223 
FluoSpheres® carboxylate modified 
microspheres, 1 µm, yellow-green 
fluorescent (505/515), 2 % solids 
Invitrogen Ldt., Paisley, UK           468445 
Dried agar Becton Dickinson Company 
Sparks, USA 
         2011008 
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Appendix B - Calculations from section 3.1 Distribution studies of 
nanoparticles in and on mucus 
 
B.1 Calculating the amounts of nanoparticles in 100 µL 200 nm sized particles and 100 
µL 100 nm sized particles 
 
The FluoSphere® nanoparticles has a concentration of 2 % (w/v), and a density of 1.05. 
 
First the 2 % (w/v) nanoparticle solutions were mixed into the mucus into an end 
concentration of 0.08 % (w/v), using equation 1. 
 
 
 
 
                        (1) 
   
In order to obtain a 0.08 % (w/v) concentrated solution, 8 µL of the 2 % nanoparticle solution 
were mixed into 200 µL of mucus. 
 
Equation 2 was used for calculating the amount of nanoparticles of the 0.08 % (w/v) solutions 
of 100 nm sized nanoparticles and 200 nm sized nanoparticles. 
 
 
                              
               (2) 
 
were  C = the concentration of suspended beads in g/mL 
         Φ = the diameter of micorspheres in µm       
          ρ = the density of the polymer in g/mL 
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The 200 nm sized nanoparticles; 
 
 
 
 
 
 
 
 
 
 
 
 
 
The number of particles in the 0.08 % (w/v) nanoparticle solution of 200 nm sized 
nanoparticles are 3.63 * 1010, which is the desired number of particles of the solution of 100 
nm sized nanoparticles. 
 
The 100 nm sized nanoparticles; 
 
 
 
 
 
 
 
 
 
Hence, 1 µL of the 2 % (w/v) 100 nm nanoparticle solution needs to be mixed into 200 µL 
mucus in order to achieve the same amount of nanoparticles when 8 µL of the 2 % (w/v) 
nanoparticle solution of the 200 nm sized nanoparticels are mixed into 200 µL to an end 
concentration of 0.08 % (w/v). 
 
With Equation 1 the end concentration of 1 µL of the 2 % nanoparticle solution in 200 µL 
were calculated to be 0.01 % (w/v). 
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B.2 Calculating the thickness of the mucus layers in the glass chambers 
 
The area of each glass chamber was 0.8 cm2, which equals 80 mm2. The working distance of 
the chosen objective of the confocal laser were 1.7 mm, meaning that was the maximum 
height the mucus samples could have in the glass chambers, not accounting for meniscus 
formation. 
 
With a maximum height of 1.7 mm, the maximum volume to be put in the glass chambers 
was calculated 
 
 
 
 
 
 
 
 
Hence, 136 µL were the maximum volume to be put in the glass chamber wells.  
When pipetting 100 µL in each glass chamber well, the height of the mucus were calculated 
 
 
 
 
 
When 100 µL of mucus were put in each well and 100 µL nanoparticle solution put on top, 
also the height and volume of the nanoparticle solutions possible to visualise were calculated 
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Appendix C - Calculations and fluorescence intensity measurements from 
section 3.2 Development of the plate method 
 
C.1 Calculation of the percentage mucus wet weight to evaporate during the drying 
procedure 
 
The following is an example on how the percentage of wet weight to have evaporated from 
the mucus during drying, were calculated. 
 
 
The measured weight of the microtitrer plate prior to addition of mucus: 50.37 g. 
The measured weight of the microtitrer plate after addition of mucus: 51.97 g 
The weight of the added mucus:  
 
 
 
 
 
The measured weight of the plate after the mucus has dried for 30 h: 50.91 g 
The weight of the mucus that has evaporated:  
 
 
 
 
 
Percentage of the mucus wet weight that has evaporated during drying:  
 
 
 
 
 
Replicate experiments yielded results that lay within 65-70 %.   
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C.2 Fluorescence intensity measurements by the plate reader 
 
C.2.1. Background fluorescence measurements on dried and fresh biosimialar mucus 
 
The results from the first fluorescence intensity measurements on different states of biosimilar 
mucus are presented in Table C.1. 
 
Table C.1 The background fluorescence intensity measurements of dried biosimilar mucus, dried 
biosimilar water with MQ-water on top and fresh biosimilar mucus. The ex./em. wave-lengths of the 
measurement were set to 495/535 nm. The lower row in the table resents the average values of the 
eight replicates.  
Dried biosimilar mucus Dried biosimilar mucus + 
MQ-water 
Fresh bisoimilar mucus 
35583 31064 30620 
39320 30962 30955 
40631 35032 30749 
45187 33084 31246 
45239 31978 30326 
38986 32963 29429 
42881 32449 30180 
39680 30957 29354 
40938.38 32311.13 30357.38 
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C.2.2 Additional background fluorescence measurements 
 
For a more thorough investigation of the background fluorescence of different states of  PSIM 
and biosimilar mucus, additional background fluorescence measurements were conducted. 
The results are presented in Table C.2, Table C.3, Table C.4 and Table C.5. 
 
Table C.2 Fluorescence intensity measurements of eight replicates of fresh biosimilar mucus, fresh 
PSIM, 5% (w/v) Sigma solution, yellow-green FluoSpheres® (0.00001 % (w/v)), red FluoSpheres® 
(0.00001% (w/v)), MQ-water and empty wells. The fluorescence measurements are performed with 
ex./em. wave-lengths of 505/545 nm, and with 200 µL sample in each well. The values of the bottom 
row are average values of the eight replicate measurements. 
Empty MQ-
water 
Sigma 
mucin 
5 % 
Biosimilar 
mucus 
PSIM yellow-green 
(0.00001 %) 
red 
(0.00001 %) 
27 29 23396 31795 40309 572 34 
17 36 24087 32250 44218 656 35 
19 28 24804 32213 43286 635 35 
17 25 24446 30025 42033 628 28 
23 22 24354 31464 39585 664 36 
26 45 24614 31860 37561 629 35 
25 26 25077 31595 40659 570 32 
29 28 23997 29449 39372 645 36 
22,875 29,875 24346,88 31331,38 40877,88 624,875 33,875 
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Table C.3 Fluorescence intensity measurements of eight replicates of fresh biosimilar mucus, fresh 
PSIM, 5% (w/v) Sigma solution, yellow-green FluoSpheres® (0.00001 % (w/v)), red FluoSpheres® 
(0.00001% (w/v)), MQ-water and empty wells. The fluorescence measurements are performed with 
ex./em. wave-lengths of 580/625 nm, and with 200 µL sample in each well. The values of the bottom 
row are average values of the eight replicate measurements. 
Empty MQ-
water 
Sigma 
mucin 
5 % 
Biosimilar 
mucus 
PSIM yellow-green 
(0.00001 %) 
red 
(0.00001 %) 
28 46 7709 8532 39823 25 987 
25 50 7919 8802 43913 42 1091 
29 70 7866 8838 43828 41 1013 
39 36 7974 8248 40532 56 965 
62 34 8083 8415 37503 58 1046 
27 48 7719 8340 31464 49 1131 
36 52 8088 8841 40866 35 1157 
47 62 7764 8164 40225 59 1060 
36,625 49,75 7890,25 8522,5 39769,25 45,625 1056,25 
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Table C.4 Fluorescence intensity measurements of eight replicates of dried biosimilar mucus (BSM), 
dried biosimilar mucus and MQ-water, fresh biosimilar mucus, dried PSIM, 5% (w/v) Sigma solution, 
yellow-green FluoSpheres® (0.00001 % (w/v)), red FluoSpheres® (0.00001% (w/v)), MQ-water and 
empty wells. The fluorescence measurements is performed with ex./em. wave-lengths of 495/535 nm. 
The volume of sample in each well was 200 µL. The bottom row gives the average fluorescent 
intensity measurements of the eight replicate samples. 
Empty MQ-
water 
Dried 
biosimilar 
mucus 
Dried 
biosimilar 
mucus + 
MQ-water 
Fresh 
biosimilar 
mucus 
Dried 
PSIM 
Sigma 
mucin 
5 % 
Yellow-
green 
(0.00001 
%) 
red 
(0.00001 
%) 
33 22 24724 35958 43923 39690 32483 2969 19 
33 21 21226 36420 42028 41618 31549 2941 19 
41 25 23172 34737 42859 36930 31453 2970 22 
36 24 17794 32317 42561 32679 31468 2907 16 
42 23 25298 35154 43115 32572 31292 2957 23 
38 29 25414 34686 43800 26385 31061 2621 18 
43 23 25906 28538 43802 29328 31016 3097 21 
36 17 21507 33232 42580 26208 30561 2958 19 
37,75 23 23130,13 33880,25 43083,5 33176,25 31360,38 2927,5 19,625 
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Table C.5 Fluorescence intensity measurements of eight replicates of dried biosimilar mucus (BSM), 
dried biosimilar mucus and MQ-water, fresh biosimilar mucus, dried PSIM, 5% (w/v) Sigma solution, 
yellow-green FluoSpheres® (0.00001 % (w/v)), red FluoSpheres® (0.00001% (w/v)), MQ-water and 
empty wells. The fluorescence measurements is performed with ex./em. wave-lengths of 580/615 nm. 
The volume of sample in each well was 200 µL. The bottom row gives the average fluorescent 
intensity measurements of the eight replicate samples. 
Empty MQ-
water 
Dried 
biosimilar 
mucus 
Dried 
biosimilar 
mucus + 
MQ-water 
Fresh 
biosimilar 
mucus 
Dried 
native 
PSIM 
Sigma 
mucin 
5 % 
Yellow-
green 
(0.00001 
%) 
red 
(0.00001 
%) 
70 162 21046 30194 38760 47268 25099 148 3919 
149 108 18959 29792 38734 45359 26427 154 4350 
146 125 19908 31681 40539 45568 26143 135 4359 
110 170 16454 32617 40567 43521 27023 151 4308 
124 147 21091 33992 40195 39693 26875 167 4190 
158 134 21875 33174 42464 35236 27191 146 4335 
155 115 21646 29404 41050 32373 28480 121 4359 
85 164 18592 30718 39455 34162 28035 159 4147 
124,62 140,62 19946,38 31446,5 40220,5 40397,5 26909,13 147,62 4245,87 
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C.2.3 Sigma mucin gradient experiments 
 
The results from the Sigma mucin gradient experiments are presented in Table C.6, Table C.7, 
Figure C.1 and Figure C.2. 
 
Table C.6 The fluorescence intensity measured in three replicates of Sigma mucin solutions of 
different concentrations (indicated by the percentages (w/v)). The bottom row presents the average 
values of the three replicates. The ex./em. wave-length of the measurement was 495/535 nm. 
Empty MQ-water 0.05 % 0.1 % 0.5 % 1 % 5 % 
38 46 505 844 4266 7629 41400 
30 42 554 896 4360 8032 43138 
31 38 539 925 4514 8347 43277 
33 42 532.67 888.33 4380 8002.67 42605 
 
Table C.7 The fluorescence intensity measured in three replicates of Sigma mucin solutions of 
different concentrations (indicated by the percentages (w/v)). The bottom row presents the average 
values of the three replicates. The ex./em. wave-length of the measurement was 580/615 nm. 
Empty MQ-water 0.05 % 0.1 % 0.5 % 1 % 5 % 
140 249 620 912 4187 7285 41307 
273 294 707 993 4041 7274 42071 
210 222 536 1147 4110 7967 42399 
207.67 255 621 1017.33 4112.67 7508.67 41925.67 
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Figure C.1 The fluorescence intensity measured in three replicates of Sigma mucin solutions of 
different concentrations (indicated by the percentages (w/v)). The ex./em. wave-length of the 
measurement was 580/615 nm. 
 
 
Figure C.2 Sigma mucin gradient The fluorescence intensity measured in three replicates of Sigma 
mucin solutions of different concentrations ). The ex./em. wave-length of the measurement was 
580/615 nm. 
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C.2.4 Fluorescence intensity measurements of differing amount of fresh PSIM and biosimilar 
mucus 
 
The background fluorescence intensity were measured for differing amounts of fresh 
biosimilar mucus and fresh PSIM, and the results are presented in Table C.8, Table C.9 and 
Figure C.3. 
 
Table C.8 Fluorescence intensity measurements of eight replicates of 100 µL amounts of fresh 
biosimilar mucus, 200 µL fresh biosimilar mucus, 100 µL fresh PSIM and 200 µL fresh PSIM. The 
ex./em. wavelengths of the measurements were 495/515 nm. 
 
100 µL PSIM 100 µL 
Biosimilar 
mucus 
200 µL PSIM 200 µL 
Biosimilar 
mucus 
29727 16723 42902 25795 
24973 18470 41400 24065 
29029 14931 35491 25491 
29820 14376 38088 25647 
32701 16784 45496 26235 
38626 15671 36721 25530 
32040 18779 37397 25931 
31191 15738 31638 24453 
 31013,38 16434 38641,63 25393,38 
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Table C.9 Fluorescence intensity measurements of eight replicates of 100 µL amounts of fresh 
biosimilar mucus, 200 µL fresh biosimilar mucus, 100 µL fresh PSIM and 200 µL fresh PSIM. The 
ex./em. wavelengths of the measurements were 580/615 nm. 
100 µL PSIM 100 µL 
Biosimilar 
mucus 
200 µL PSIM 200 µL 
Biosimilar 
mucus 
34678 19865 37784 23881 
30064 21864 36153 23846 
33877 16858 31850 23732 
36364 17615 33078 23052 
36978 20371 37669 23604 
43429 18118 31784 23583 
38283 21037 32094 23619 
35983 17823 27363 22468 
36207 19193,88 33471,88 23473,13 
 
 
 
Figure C.3 Fluorescence intensity measurements of eight replicates of 100 µL amounts of fresh 
biosimilar mucus, 200 µL fresh biosimilar mucus, 100 µL fresh PSIM and 200 µL fresh PSIM. The 
ex./em. wavelengths of the measurements were 580/615 nm.  
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Appendix D – Rheological measurements from section 3.3.5 Control 
rheological measurements of Sigma mucin solutions 
 
The results of the rheological measurements of the Sigma mucin solutions not presented in 
Results and Discussion section 3.3.5, is presented in this Appendix. 
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D.1 Rheolgical measurements of the Sigma mucin solutions – strain sweeps 
 
 
Figure D.1 Stain sweep of a 5 % (w/v) Sigma mucin solution in the strain range 0.001-100. The 
temperature of the measurement were 25 °C, and the frequency 1 Hertz. 
 
 
Figure D.2 Stain sweep of an 8 % (w/v) Sigma mucin solution in the strain range 0.001-100. The 
temperature of the measurement were 25 °C, and the frequency 1 Hertz. 
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Figure D.3 Stain sweep of a 10 % (w/v) Sigma mucin solution in the strain range 0.001-100. The 
temperature of the measurement were 25 °C, and the frequency 1 Hertz. 
 
 
Figure D.4 Stain sweep of a 5 % (w/v) Sigma mucin solution in the strain range 0.001-100. The 
temperature of the measurement were 37 °C, and the frequency 1 Hertz. 
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Figure D.5 Stain sweep of an 8 % (w/v) Sigma mucin solution in the strain range 0.001-100. The 
temperature of the measurement were 37 °C, and the frequency 1 Hertz. 
 
 
Figure D.6 Stain sweep of a 10 % (w/v) Sigma mucin solution in the strain range 0.001-100. The 
temperature of the measurement were 37 °C, and the frequency 1 Hertz. 
 XXII 
 
	  
Appendix	  D	  
	  
	   	  
D.2 Rheolgical measurements of the Sigma mucin solutions – frequency sweeps 
 
 
Figure D.7 Frequency sweep of a 5 % (w/v) Sigma mucin solution in the frequency range 0.001-100 
Hertz. The temperature of the measurement were 15 °C, and the strain fixed to 0.05. 
 
Figure D.8 Frequency sweep of an 8 % (w/v) Sigma mucin solution in the frequency range 0.001-100 
Hertz. The temperature of the measurement were 15 °C, and the strain fixed to 0.05. 
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Figure D.9 Frequency sweep of a 10 % (w/v) Sigma mucin solution in the frequency range 0.001-100 
Hertz. The temperature of the measurement were 15 °C, and the strain fixed to 0.05. 
 
 
Figure D.10 Frequency sweep of a 5 % (w/v) Sigma mucin solution in the frequency range 0.001-100 
Hertz. The temperature of the measurement were 25 °C, and the strain fixed to 0.05. 
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Figure D.11 Frequency sweep of an 8 % (w/v) Sigma mucin solution in the frequency range 0.001-
100 Hertz. The temperature of the measurement were 25 °C, and the strain fixed to 0.05. 
 
Figure D.12 Frequency sweep of a 10 % (w/v) Sigma mucin solution in the frequency range 0.001-
100 Hertz. The temperature of the measurement were 25 °C, and the strain fixed to 0.05. 
